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Abstract 
Infection has been identified as both a chronic and acute risk factor of 
cardiovascular disease (CVD). Despite the growing body of evidence, additional research 
elucidating the relationship between infection and CVD is needed. This dissertation 
employs longitudinal data from the Atherosclerosis Risk in Communities (ARIC) study, 
the Longitudinal Investigation of Thromboembolism Etiology (LITE) ancillary study, the 
Dental-ARIC (D-ARIC) ancillary study, and the corresponding ARIC study participant 
Centers for Medicare and Medicaid Services (CMS) data to examine the relationship 
between infection and CVD. 
In the first manuscript we assessed the longitudinal relationship between self-
reported periodontal disease and clinical periodontal disease and incident venous 
thromboembolism (VTE). Self-reported periodontal disease was associated with 30% 
higher VTE risk that remained significant or borderline significant after adjustment. 
Crude associations between clinical periodontal disease classifications were attenuated 
with adjustment and were no longer significant.  
In the second manuscript we assessed the longitudinal relationship between 
history of endodontic therapy (ET) and incident coronary heart disease (CHD), ischemic 
stroke, heart failure, and VTE. We found no significant associations between self-
reported history of ET and any of our outcomes of interest that remained after 
adjustment.  
 In the final manuscript we used a case-crossover study design to evaluate infection 
as a potential trigger of CHD, ischemic stroke, and VTE. Infection was associated with 
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higher odds of CHD, stroke, and VTE up to 90 days following the infection. The 
association between infection and CVD/VTE was graded such that the infection-
CVD/VTE association was highest immediately following the infection and decreased as 
the time since the infection increased. Generally, outpatient infection was a weaker 
CVD/VTE trigger compared to all infections. 
 Further research is needed to pinpoint if periodontal disease is independently 
associated with VTE risk and if periodontal prevention and treatment could reduce VTE 
risk. Our results do not support an independent association between endodontic therapy 
and CVD or VTE. The results of the third manuscript provide evidence in support of our 
hypothesis that infection is a CVD/VTE trigger. Patients with an infection who are at 
elevated risk of CVD should be considered potential candidates for CVD prophylaxis 
during and immediately after infection to reduce the otherwise elevated CVD/VTE risk.  
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Chapter 1 – Background 
Overview of Cardiovascular Disease 
Cardiovascular disease (CVD), including coronary heart disease (CHD) and 
stroke is the leading cause of death and disease burden worldwide.1 An estimated 17.5 
million people die from CVD annually, representing 31% of all global deaths.2 In the 
United States, CVD is the leading cause of death for both men and women accounting for 
around 610,000 deaths each year.3 CHD is the most common type of heart disease in the 
United States and is responsible for killing over 365,000 people annually.3 CVD is also 
the largest source of disability and premature death and the leading source of disability 
adjusted life years (DALYs) for both men and women in the U.S.4 Nearly 20% of CVD 
related deaths occur in persons younger than 65 and 35% occur before age 75.3 
As a result of the health burden associated with CVD, a great deal of 
epidemiologic research has been devoted to identifying and describing CVD risk factors. 
Population-based cohort studies have identified many chronic risk factors for 
cardiovascular disease (CVD) that are both modifiable including high blood pressure, 
elevated serum cholesterol, and smoking, and non-modifiable including male sex, non-
white race, family history, and greater age.5-7 Further, acute risk factors – or triggers – of 
CVD events have been identified including physical exertion, stress, sexual activity, 
alcohol abuse, and drug use among others.8, 9 Infection has been proposed as both a 
chronic and acute risk factor of CVD. 
Infectious Diseases and Cardiovascular Disease 
Infection is defined as the entry and development or multiplication of an 
infectious agent in the body of human or animal.10 Each year, infections are associated 
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with an estimated 20.2 million outpatient visits and 3.9 million inpatient visits in the 
United States.11 Numerous studies have examined the impact of both chronic and acute 
infections on CVD outcomes. In their review of infection and stroke evidence, Miller and 
Elkind conclude that there is evidence that a number of infections can directly cause 
CVD, including bacterial, fungal, parasitic, and viral.12 While a comprehensive review of 
the evidence is beyond the scope of this work, understanding the existing evidence 
related to infection and CVD is important.  
Chronic Infection and CVD 
 Extensive work has been done to identify associations between chronic infections 
and CVD including viral infections like cytomegalovirus, herpes, hepatitis C, and HIV, 
and bacterial infections like chlamydia pneumoniae, osteomyelitis, and helicobacter 
pylori among others.  
The association between cytomegalovirus (CMV) and CHD has also been meta-
analyzed. Ji et al found that people exposed to CMV infection had 1.67 times the odds of 
CHD compared to unexposed persons.13 Herpes simplex virus (HSV) infection has also 
been studied as a CVD risk factor in a meta-analysis. Wu et al found that participants 
exposed to HSV-1 infection exhibited an increased risk of atherosclerosis (OR = 1.77) 
while HSV-2 positive participants also demonstrated significantly increased 
athersclerosis risk (OR = 1.37).14 The impact of hepatitis C viral infection (HCV) on 
CVD was recently assessed in a meta-analysis conducted by Petta et al. They found that 
HCV-infected patients had increased risk of CVD-related mortality (OR = 1.65) and 
stroke (OR = 1.30).15 Another meta-analysis conducted in 2016 by Olubamwo et al found 
that the risk of developing coronary atherosclerosis among persons with chronic hepatitis 
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C is about triple compared to uninfected persons (OR = 3.06).16 Considering HIV, Islam 
et al conducted a meta-analysis and found that CHD was 61% higher among people 
infected with HIV compared to uninfected people.17    
Extensive research and meta-analyses have also been done to evaluate the impact 
of bacterial infections on CVD. In 2015, Corrales-Medina et al used data from the 
Atherosclerosis Risk in Communities (ARIC) study to evaluate the impact of hospitalized 
pneumonia on CVD. They concluded that pneumonia is both an acute and chronic risk 
factor for CVD.18 Two prior meta-analyses also found associations between chlamydia 
pneumoniae and cardiovascular disease. Danesh et al found that the presence of 
chlamydia pneumoniae IgA titres was associated with a 25% increase in CHD risk.19 
Simlarly, Smieja et al found that the prevalence of circulating chlamydia pneumoniae 
DNA was associated with a 2-fold increase in CVD.20 A recent meta-analysis of 
pneumonia and stroke conducted by Su et al showed that pneumonia infection was 
significantly associated with a two-fold increase in ischemic stroke risk.21 Considering 
osteomyelitis and CHD, Hsiao et al found that the risk of CHD was 1.65 times higher 
among patients with chronic osteomyelitis compared to control patients.22 Two recent 
meta-analyses of studies looking at helicobacter pylori (H. pylori) and CHD have been 
done. Sun et al found that H. pylori infection increases CHD risk by 11%.23 Liu et al 
found that H. pylori is associated with a 2-fold increase risk of myocardial infarction 
(MI).24 An earlier meta-analysis conducted by Zhang et al found that H. pylori infection 
increases CHD risk (OR = 2.11) and ischemic stroke (OR = 2.68).25 Two more recent 
meta-analses done byYu et al26 and Wang et al27 found a pooled OR=1.97 and OR = 1.60 
respectively between H. pylori and stroke.  
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Oral Infections 
Among the infections proposed to be associated with CVD are oral infections. 
Caplan wrote in 2004 that “perhaps the most exciting issue currently facing the dental 
research community centers around a hypothesized connection between chronic 
inflammatory oral infections, most notably periodontal disease, and the development of 
adverse systemic health conditions.”28 The two most prominent dental infectious diseases 
are periodontal disease (periodontitis) which affects one or more of the periodontal 
tissues supporting the tooth and endodontic infection in which bacteria infect the tooth’s 
pulp chamber and leads to apical periodontitis or infection of the apex of the tooth root.   
Periodontal Disease 
Periodontal disease is a chronic inflammatory disease caused by bacterial 
infection of the supporting tissues around the teeth.29 Periodontal disease is characterized 
by inflammatory destruction of the tissues supporting the teeth including gingival tissue, 
periodontal ligaments, and alveolar bone (see Figure 1 below).30  
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Figure 1. Periodontal disease anatomy and pathology 
 
 
Symptoms of periodontal disease include bad breath, red or swollen gums, tender 
or bleeding gums, painful chewing, tooth lose or sensitivity, and receding gums or longer 
appearing teeth.31 Treatment options depend on the severity of the disease but all aim to 
control the infection. Scaling is a procedure that involves removing plaque and tartar 
from the teeth both above and below the gum line. Root planing gets rid of rough spots 
on the tooth root where bacteria can gather. Scaling and root planning are used together 
to prevent and remove the bacteria that contribute to periodontal diease.31 Antibiotic 
medications are also used. Surgical procedures are the most comprehensive form of 
treatment. Flap surgery involves lifting back the gums to remove tartar and then suturing 
the gums back in place snugly around the teeth. Bone and tissue graft surgery can be 
performed to help regenerate bone or gum tissue lost as a result of the infection.31   
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Periodontitis is common with around half of all US adults having some 
periodontitis and nearly 10% having severe periodontitis.32 Periodontal disease is 
positively associated with increasing age and is higher among males compared to 
females.32 Prevalence is highest in Hispanics (63.5%) and non-Hispanic blacks (59.1%), 
followed by non-Hispanic Asian Americans (50.0%), and lowest in non-Hispanic whites 
(40.8%).32 Prevalence is higher in those of low socioeconomic status (SES) compared to 
high SES individuals.32 Other risk factors for periodontal disease include poor oral 
hygiene, inadequate dental care, cigarette smoking, systemic conditions such as diabetes 
mellitus, osteoporosis, rheumatoid arthritis, and possibly obesity, stress, and poor coping 
behaviors.33 Periodontitis is a significant contributor to tooth loss among adults in the 
United States.34 
Periodontal infection has been measured using multiple approaches in past 
epidemiologic studies. Previous studies of periodontal disease and CVD have used self-
reported periodontal disease status ascertained using participant questionnaires.35 While 
this is perhaps the easiest and most efficient way to gather exposure data, self-reported 
disease status can suffer from measurement error since participants may not know their 
current disease status and past disease information may not be remembered and reported 
accurately. 
Periodontitis has also been assessed using radiography to calculate the bone loss 
associated with the disease.36 Another method for measuring periodontal disease is 
through identifying the presence of systemic antibody titers. Using ARIC data, Beck et al 
used systemic antibody levels to assess the cross-sectional relationship between 
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periodontal microbes and coronary heart disease.37 Similarly, other studies have 
measured periodontal microbes in periodontal plaque samples.38     
Clinical examinations have also been frequently used to assess periodontal disease 
status in the context of studies exploring the association between periodontal disease and 
CVD. Clinical diagnosis of periodontal disease is based on severity and extent of clinical 
attachment loss and probing depth. Bleeding upon probing is also frequently used in the 
clinical assessment of periodontal disease. The most common clinical assessment case 
definition was created by the Center for Disease Control and Prevention (CDC) 
Periodontal Disease Surveillance workgroup in collaboration with the American 
Academy of Periodontology (CDC/AAP).39  
The CDC/AAP 4-level case definition is as follows:  
1. No periodontitis: No evidence of mild, moderate, or severe periodontitis 
2. Mild periodontitis: ≥2 interproximal sites (area between teeth) with attachment 
loss ≥3 mm, and ≥2 interproximal sites with probing depth ≥4 mm (not on same 
tooth) or one site with probing depth ≥5 mm 
3. Moderate periodontitis: ≥2 interproximal sites with attachment loss ≥4 mm (not 
on same tooth), or ≥2 interproximal sites with probing depth ≥5 mm (not on same 
tooth) 
4. Severe periodontitis: ≥2 interproximal sites with attachment loss ≥6 mm (not on 
same tooth) and ≥1 interproximal site with probing depth ≥5 mm 
 Recently, a new clinical periodontal disease classification has been proposed by 
Morelli et al.40 It uses 7 tooth-level clinical parameters (interproximal attachment level, 
probing depth, bleeding on probing, gingival inflammation index, plaque index, the 
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presence/absence of full prosthetic crowns for each tooth, and tooth status presence) to 
identify seven distinct periodontal profile classes (PPC) as follows: 
1. PPC-A: Health 
2. PPC-B: Mild Disease 
3. PPC-C: High Gingival Inflammation Index  
4. PPC-D: Tooth Loss 
5. PPC-E: Posterior Disease 
6. PPC-F: Severe Tooth Loss 
7. PPC-G: Severe Disease 
Periodontal Disease and CVD 
 Multiple studies have reported an association between periodontal infection and 
increased risk of coronary heart disease (CHD) and cardiovascular disease (CVD). 
Previous studies have used a variety of study designs to test whether there is an 
association between periodontal disease and CVD including cross-sectional,37, 41-51 case-
control,36, 52-63 and cohort studies.35, 64-81 Multiple meta-analyses have considered the 
possible role of periodontal disease in the etiology of CHD.82, 83 The most recent meta-
analysis conducted by Leng et al in 2015 found that among 230,406 participants from 15 
studies, periodontal disease was significantly and independently associated with an 
increased risk of CHD with a pooled RR = 1.19.83 Earlier meta-analyses also found a 
significant and independent association between periodontal disease and CHD including 
Blaizot et al82 (RR = 1.34), Humphrey et al84 (RR = 1.24), Mustapha et al85 (OR = 1.75), 
Bahekar et al86 (RR = 1.14), Khader et al87 (RR = 1.15), and Janket et al88 (RR = 1.19).  
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 In addition to meta-analyses, recent studies not included in the previous meta-
analyses have also identified independent associations between periodontal disease and 
CVD. In 2016, Hansen et al used data from a Danish nationwide cohort and found that 
individuals with periodontitis had increased risk of cardiovascular death (IRR = 2.02) and 
total mortality (IRR = 2.70).81 Another study published in 2017 by Beukers et al used the 
electronic health records of 60,174 participants in the Netherlands to study the cross-
sectional association between periodontal disease and CVD. They found an independent 
association between periodontal disease and atherosclerotic cardiovascular diseases (OR 
= 1.59).51 The PAROKRANK study recently published results from their case-control 
study that found an increased risk for a first MI among those with periodontal disease 
(OR = 1.28) compared to those without periodontal disease.36 
 ARIC data have also been used to study the cross-sectional association between 
periodontal disease and CHD. Elter et al found that ARIC participants with both high 
periodontal attachment loss and high tooth loss (OR = 1.5) and edentulous individuals 
(OR = 1.8) had elevated odds of prevalent CHD compared to individuals with low 
attachment loss and low tooth loss, while controlling for a number of traditional CHD 
risk factors.48 A more recent cross-sectional study using ARIC data performed by Beck et 
al found that clinical signs of periodontal disease were not associated with prevalent 
CHD while systemic periodontal antibody response was associated with prevalent 
CHD.37      
 Previous studies have also explored the potential association between periodontal 
disease and stroke. In 2012, Sfyroeras et al conducted a meta-analysis and found that the 
adjusted stroke risk in participants with periodontitis was 1.47 times higher than in 
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participants without periodontitis.89A more recent meta-analysis conducted by Lafon et al 
found that stroke risk was significantly increased by the presence of periodontitis (RR = 
1.63).90 In 2016, Leira et al published a meta-analysis of 8 studies that found a 
statistically significant association between periodontal disease and ischemic stroke in 
both cohort studies (RR = 2.52) and case-control studies (RR = 3.04).91 Cross-sectional 
ARIC data have also been used to study the relationship between periodontal disease and 
stroke. A 2003 paper by Elter et al found that the highest quartile of periodontal 
attachment loss was associated with prevalent stroke and TIA (OR = 1.3).92 
 Despite the preponderance of existing evidence linking periodontal disease to CHD 
and stroke, a potential association between periodontal disease and venous 
thromboembolism (VTE), has received less research attention. Only one previous study 
considered a possible association between periodontal disease and VTE. Sanchez-Siles et 
al. used a case-control study design in which 97 patients with VTE and 100 healthy 
controls were compared for prevalent periodontal disease. They found that periodontitis 
was more prevalent in VTE patients than controls (p<.001).93 Studies of periodontal 
disease and CVD published since 2014 are summarized in Table 1 below.  
Table 1. Summary of studies on periodontal disease and CVD since 2014 
Study Year Study Design Outcome Association (95% CI) 
Hansen et al81 2016 
Retrospective 
Cohort 
MI IRR=1.44 (1.30,1.60) 
Ischemic Stroke IRR=1.89 (1.74,2.05) 
Cardiovascular Death IRR=2.54 (2.36, 2.72) 
CHD IRR=2.03 (1.92, 2.14) 
All-Cause Mortality IRR=3.20 (3.09, 3.32) 
Beukers et al51 2016 Cross-Sectional CHD OR=1.59 (1.39, 1.81) 
Rydén et al.36 2016 Case-Control MI OR=1.29 (1.03, 1.60) 
Leira et al 91 2016 Meta-Analysis Ischemic Stroke 
Cohort RR=2.52 (1.77, 
3.58) 
Case-Control RR=3.04 
(1.10, 8.43) 
Leng et al83 2015 Meta-Analysis CHD RR = 1.19 (1.13, 1.26) 
Lafon et al90 2014 Meta-Analysis All Strokes RR=1.63 (1.25, 2.00) 
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Endodontic Infection (EI) and Apical Periodontitis (AP) 
Endodontic infection (EI) is caused by bacteria or their byproducts entering a 
tooth’s pulp chamber at the apex of the tooth root.94 The infected root canal constitutes 
the main source of persistent microbial irritation to the periradicular tissues which can 
lead to apical periodontitis (AP), which is the inflammation and destruction of 
periradicular tissues and infection abscesses surrounding the root end of a tooth (see 
Figure 2 below).95, 96    
Figure 2. Endodontic anatomy and pathology 
    
The most common symptoms of EI/AP are pain, tenderness, and inflammation 
around the infection site but EI/AP can also be asymptomatic.97 Treatment options for 
EI/AP include antibiotics which may ease the symptoms but do not typically eradicate the 
infection.98 Endodontic therapy (root canal) or tooth extraction is typically required to 
permanently address EI/AP.98  
 12 
 
EI/AP is relatively common. Previous studies in western countries have estimated 
that the prevalence in adults is between 14% and 70%.28 A recent study conducted in 
Finland found that 27% of adults had one or more teeth with EI/AP.99 EI/AP is positively 
associated with age and is higher among males compared to females.99 Individual risk 
factors for EI/AP include poor oral hygiene, inadequate dental care, and cigarette 
smoking as well as dental risk factors, such as root canal interventions, pulpal posts, 
inadequate crowns or coronal fillings, primary carious lesions, and reduced marginal 
bone level.100 
 EI/AP has been measured using multiple approaches in past epidemiologic 
studies. Clinically, EI/AP is diagnosed through observation of periapical bony lesions on 
radiographs (indicative of chronic endodontic inflammation) or of radiopaque material in 
the root canal system (indicative of a history of root canal therapy).94 Radiographic 
diagnosis has been used by multiple epidemiologic studies in the past.101-103 Studies using 
clinical EI/AP definitions require dental exams and thus often have small sample sizes to 
accommodate efficient data collection. Researchers often do not have access to 
participants’ radiographs and may be unable to collect radiographs for research purposes 
due to the cost, required resources, and ethics associated with radiation exposure for 
research purposes, particularly in large study samples.28  
In the absence of radiographic information, one way to estimate history of EI/AP 
is through participants’ self-reports of endodontic therapy (ET). Use of self-reported ET 
as a proxy for EI/AP has limitations.94, 103 First, ET could be performed for restorative 
reasons such as prophylaxis in trauma cases and not endodontic reasons. Also, a lack of 
ET does not necessarily imply the absence of EI/AP since teeth could be extracted or 
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remain asymptomatic. Further, individuals who have not received or do not have access 
to dental care may not receive ET when it would be otherwise warranted. Finally, 
misclassification of exposure could take place since historical ET may be forgotten or 
mistaken for other procedures. 
Despite the limitations, self-reported history of ET has been used as a proxy for 
EI/AP in the past.94, 104 Two studies have evaluated the validity of self-reported history of 
ET compared to radiographic verified ET. In 2002, Pitiphat et al. compared self-reported 
measures obtained by a self-administered questionnaire with measures simultaneously 
obtained with clinical and radiograph examinations. They found that self-reported history 
of root canal therapy had 90% sensitivity, 94% specificity, a positive predictive value of 
86% and a negative predictive value of 95%  among 58 adult patients to the Harvard 
School of Dental Medicine student dental clinic.105 They conclude that self-reports of ET 
provide reasonably valid estimates of past root canal therapy (ET). A more recent study 
conducted by Gomes et al compared self-reported history of ET with ET status 
determined simultaneously from panoramic radiographs. They found that self-reported 
history of ET had 92% sensitivity, 89% specificity, 82% positive predictive value, and 
95% negative predictive value.106 The authors concluded that self-reported history of ET 
is a highly accurate method to predict historic ET.106                 
Endodontic Infection (EI)/Apical Periodontitis (AP) and CVD 
The association between EI/AP and CVD has not been studied as extensively as 
periodontal disease and CVD. Previous studies have only considered the impact of EI/AP 
on CHD and have not yet considered the impact of EI/AP on other CVD outcomes. 
Additionally, the evidence linking EI/AP is inconsistent. The majority of previous studies 
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have found an association between EI/AP and increased risk of CHD94, 101, 103, 107-110 while 
some studies failed to find an association between EI/AP and CHD47, 111 and others were 
inconclusive.102, 104, 112  
Three studies published in 2016 evaluated the association between EI/AP and 
CHD. Liljestrand et al used cross-sectional data from the 508 patients enrolled in the 
Finnish Parogene study and found that EI was independently associated with CHD (OR = 
1.94) and with acute coronary syndrome (OR = 2.46).101 Gomes et al used a retrospective 
cohort from the Baltimore Longitudinal Study of Aging and found that EI was 
independently associated with CHD (RR = 1.77).102 Finally, An et al used a case-control 
study design and electronic medical record data and also found an independent 
association between AP and CHD (OR = 5.3).103  
ARIC data have also been used to study the relationship between EI/AP and 
prevalent CHD. In 2009, Caplan et al conducted a cross-sectional study and found that 
among participants with 25 or more teeth, those reporting having had ET two or more 
times had 1.62 times higher odds of CHD compared with those reporting never having 
had ET.94   
Despite the previous work devoted to understanding EI/AP and CHD, to our 
knowledge no studies have directly addressed the association between EI/AP and stroke, 
heart failure, or VTE. Additionally, most studies relied on cross-sectional or case-control 
study designs and prospective data are lacking. Studies of EI/AP and CVD published 
since 2014 are summarized in Table 2 below.   
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Table 2. Summary of studies on EI/AP and CVD since 2014 
Study Year Study Design Outcome Association (95% CI) 
Liljestrand et al101 2016 Cross-Sectional CHD OR=2.46 (1.09, 5.54) 
 
Gomes et al102 2016 Retrospective 
Cohort 
CVD RR=1.77 (1.04, 3.02) 
An et al103 2016 Cross-Sectional CVD OR=5.3(1.5, 18.4) 
Petersen et al108 2014 Cross-Sectional Aortic Atherosclerotic 
Burden 
OR=1.61 (1.39,1.86) 
Costa et al109 2014 Cross-Sectional CHD RR= 2.79 (1.1, 7.3) 
Willershausen et al110 2014 Case-Control MI OR=1.54 1.10, 2.16) 
 
Infection as a CVD Trigger 
In addition to chronic and oral infections, infections have been studied as acute 
precipitants or triggers of CVD events. In their seminal paper, Smeeth et al conducted a 
large prospective study using data from the United Kingdom General Practice Research 
Database to investigate MI and stroke risk following acute infection. They found that risk 
of MI increased by a factor of 5 and stroke risk increased by a factor of 3 in the days 
following an acute upper respiratory infection, and to a lesser degree after a urinary tract 
infection. Risk gradually fell during the following weeks.113  
Since then, numerous studies have sought to elucidate the triggering association 
between acute infections and CVD. In 2014, Dalager-Pedersen et al conducted a case-
control study and determined that the risk of MI and stroke was greatly increased within 
30 days of community-acquired bacteremia (RR = 17.70 compared to population 
controls, RR = 2.32 compared to hospitalized controls) but decreased within 6 months of 
infection.114 Considering influenza infection and MI, Warren-Gash et al used electronic 
medical records and a case-crossover study design and found that MI risk was 
significantly raised during days 1-3 after acute respiratory infection (IRR = 4.19) with the 
effect tapering over time.115 A 2012 study by Guan et al used antibody levels to detect 
past infection and found that the risk of MI was associated with the presence of IgG 
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antibodies to influenza virus A (OR = 5.5) and influenza virus B (OR = 20.3).116 Another 
case-crossover study was done by Chew et al in 2012 and found an increased risk of 
acute coronary syndrome (OR = 7.5) 0-7 days following an infection compared to 7-8 
weeks following an infection.117 ARIC data were combined with the Cardiovascular 
Health Study (CHS) to study triggering by infection. Corrales-Medina et al found that 
CVD risk after pneumonia was highest in the first 30 days following infection (HR = 
4.07) and decreased over time.18              
Previous studies have also examined infection as a trigger of ischemic stroke. 
Dalager-Pedersen et al’s 2014 study concluded that stroke risk is greatly increased within 
30 days of community-acquired bacteremia (RR =  25.82 compared to population 
controls, RR = 2.41 compared to hospitalized controls) but decreases over time.114 A 
study published in 2016 by Cowan et al used ARIC data and a case-crossover study 
design to show that within a population-based cohort, ischemic stroke risk is higher after 
hospitalization with infection.118 Similar results where shown by Elkind et al using CHS 
data119 and Fullerton et al using VIPS data.120 
Infection as a trigger for VTE has received less research attention. A 2017 study 
by Cowan et al found an independent increase in VTE risk following a hospitalized 
infection (OR ~ 2.0) that decreased over time.121 A previous study by Chen et al found an 
association between bacteremia and VTE (OR = 1.9).122 An earlier study by Dalager-
Pedersen et al found an association between pneumonia and both deep vein thrombosis 
(DVT) (HR = 1.78) and pulmonary embolism (PE) (HR = 1.97).123  Rogers et al. used a 
case-crossover design to measure infection as a potential VTE trigger. They found that 
the adjusted incidence rate ratio for infection during the 90-day period before 
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hospitalization for VTE compared with infection during the control period was 2.90.124 
Studies of infection as a CVD trigger published since 2014 are summarized in Table 3 
below.    
Table 3. Summary of studies of infection as a CVD trigger since 2014 
Study Year Study Design Exposure Outcome Association (95% CI) 
Dalager-
Pedersen 
et al114 
2014 Case-Control Bacteremia MI and 
Stroke 
Population Controls MI RR 
= 20.86 (15.38, 28.29) 
Hospital Controls MI OR = 
2.18 (1.80, 2.65)  
Cowan et 
al118 
2016 Case-
Crossover 
Inpatient 
Infections 
Ischemic 
Stroke 
14-day OR = 7.7 ( 2.1–27.3) 
30-day OR = 5.7 (2.3–14.3 
42-day OR = 4.5 (2.0–10.2) 
90-day OR = 3.6 (2.1–6.5) 
Fullerton 
et al120 
2015 Case-Control All Infections 
and 
Infection 
Vaccinations 
Ischemic 
Stroke 
Infection OR = 6.3 (3.2, 
12.0) 
Poorly Vaccinated OR = 8.2 
(2.5, 26.0) 
Masrouha 
et al123 
2016 Prospective 
Cohort 
Pneumonia DVT 
and PE 
DVT – OR = 1.67 (1.32, 
2.11) 
PE – OR = 2.18 (1.48, 3.22) 
Chen et 
al125 
2015 Retrospective 
Cohort 
Pneumonia  DVT 
and PE 
DVT – HR = 1.78 (1.39, 
2.28) 
PE – HR = 1.97 (1.43, 2.72) 
Dalager-
Pedersen 
et al122 
2014 Prospective 
Cohort 
Community 
Acquired 
Bacteremia 
VTE OR = 1.9 (1.4, 2.7) 
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Chapter 2 – Mechanisms Linking Infection and CVD 
 Given the evidence of an association between both chronic and acute infections and 
CVD, substantial work has been done to elucidate the mechanisms linking infection and 
CVD. While a comprehensive review of the previous research is beyond the scope of this 
work, a summary of the relevant mechanisms and pathways is important.  
 Systemic infection refers to an infection that affects the entire body as microbes and 
their byproducts can gain systemic access via the circulatory system.126 Evidence of 
infectious agents has been identified in studies of cardiovascular health. In 1999 Chiu 
identified multiple infectious agents in carotid endarectomy specimens and their 
corresponding atherosclerotic plaques.127 Similarly, Haraszthy et al. studied carotid 
endarectomy specimens and detected the presence of periodontal pathogens in 
atherosclerotic plaques.128  
 Systemic infection and the subsequent immune system response induce a 
proinflammatory condition connected to multiple proposed mechanisms linking infection 
and cardiovascular disease.  
 First, vascular endothelial cells can be infected directly, initiating the inflammatory 
response inducing atherosclerosis. Infectious agents could accelerate or enhance the 
atherosclerotic process through recruitment and stimulation of proinflammatory cytokine 
proteins — such as IL-6, IL-1β, tumour necrosis factor, complement proteins, C-reactive 
protein (CRP), serum amyloid A-1 protein, coagulation proteins and fibrinogen and tissue 
growth factors in the arterial wall, as well as enhancement of lipid accumulation through 
stimulation of macrophage scavenger or LDL-receptors.129 Damage to the vascular wall 
causes the expression of vascular cell adhesion molecule 1 and intercellular adhesion 
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molecule 1 by endothelial cells, causing monocytes to bind to the endothelium, 
transmigrate into the vessel wall and differentiate into macrophages.130 Macrophages 
contribute to the inflammatory cascade, leading to the recruitment of more macrophages 
into the vessel wall. Some macrophages also become lipid-laden foam cells, promote 
smooth muscle cell proliferation and migration, disorganization of the matrix membrane, 
and further endothelial cell dysfunction. Infectious agents acting directly on endothelial 
cells can induce thrombosis, and contribute to the formation and maturation of 
atherosclerotic plaques. 
 Infectious microbes could also indirectly influence the development and progression 
of atherosclerosis without directly invading the arterial endothelium. Release of 
endotoxin or lipopolysaccharide into the circulation could indirectly damage vascular 
endothelium or the immune response, and systemic cytokine release could result in lipid 
profile predisposing to atherosclerosis or could predispose the arterial environment to a 
procoagulant state.129 Infection leads to the overexpression of tissue factor which 
activates factor X, an activator of thrombin. Activated factor X and thrombin induce 
coagulation and mediate the inflammatory response by acting on protease-activated 
receptors expressed on endothelial cells, platelets and leukocytes.130 Other inflammatory 
cytokines impacted by infection, including IL-1β, IL-6, and TNF can also activate 
coagulation and inhibit fibrinolysis.  
Figure 3 below, which summarizes the mechanisms linking infection and CVD, 
was taken from Fong et al.129 It is also worth considering the epidemiologic evidence 
supporting the proposed mechanisms linking infection and CVD. Substantial evidence 
from previous studies has accumulated related to the relationship between infection and 
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systemic inflammation, atherosclerotic development, and platelet aggregation and 
hypercoagulability and the relationship between these mechanisms and CVD.82   
Figure 3. Mechanisms linking infection and CVD 
 
Inflammation 
 Infection impacts CVD through systemic inflammation. Multiple studies have found 
independent associations between infection and inflammatory markers. A meta-analysis 
conducted by Filardo et al found that CRP, IL-6, and fibrinogen levels were significantly 
higher in participants with pneumonia compared to participants without pneumonia.131 
Considering HIV infection and inflammatory markers, the meta-analysis by Vos et al 
found that HIV infection was associated with higher levels of C-reactive protein (CRP), 
interleukin-6 (IL-6) and d-dimer compared to uninfected persons.132 
 Existing studies have shown that periodontitis is associated with levels of systemic 
inflammatory markers including interleukin-6 (IL-6)133, C-reactive protein (CRP)133, 134 
and soluble intercellular adhesion molecule-1 (sICAM-1).135 A meta-analysis performed 
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by Freitas et al found that periodontal treatment was independently associated with higher 
CRP levels.136 Similarly, a meta-analysis conducted in 2013 by Gomes et al found that 
AP was independently associated with increased levels of CRP, IL-1, IL-2, IL-6, 
asymmetrical dimethylarginine, IgA, IgG, and IgM.137   
 Previous work on the association between inflammatory markers and CVD has been 
extensive. A number of previous studies have found associations between inflammatory 
markers and CVD. In their seminal paper and meta-analysis, Danesh et al found that 
fibrinogen, CRP, albumin, and leukocyte count were all independently associated with 
CHD.138 More recent meta-analyses have found additional inflammatory markers that are 
associated with CVD and expanded understanding of inflammation as a CVD risk 
factor.139-141 An association between inflammatory markers and VTE has also been 
established.142 Inflammatory markers have also been shown to be predictive of future 
cardiovascular risk.143, 144  
Atherosclerotic Development 
 Multiple studies have identified an association between infection and atherosclerotic 
development.145-147 A meta-analysis performed by Huang et al found an independent 
association between hepatitis C infection and carotid atherosclerosis.148 Periodontal 
disease is also independently associated with atherosclerotic development. Zeng et al 
recently performed a meta-analysis and found an independent association between 
periodontal disease and carotid atherosclerosis.149 Earlier meta-analyses found positive 
associations between periodontal treatment and makers of endothelial function and 
atherosclerosis.150, 151   
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Platelet Aggregation/Hypercoagulability 
 Infection can influence CVD by increasing platelet aggregation and 
hypercoagulability. Liang et al found that persons infected with HIV had increased 
monocyte platelet aggregates compared to uninfected persons.152 Perumal et al found an 
association between platelet activation and chronic periodontitis.153 Similarly, Banthia et 
al found that periodontal therapy was associated with a decrease in coagulant markers 
including leukocyte count, differential leukocyte count, and platelet count.154 Roth et al 
studied human aortic endothelial cells and found that P. gingivalis is associated with 
markers of both coagulation and thrombosis.155 Animal models have also found 
associations between infection and platelet aggregation and hypercoagulation.156, 157  
 Infections that gain access to the entire body through the circulatory system may 
impact CVD through systemic inflammation that leads to platelet aggregation and 
hypercoagulability and atherosclerotic development.   
Summary of Background and Rationale 
 While the existing evidence linking periodontal disease and CHD and stroke is 
promising, a potential association between periodontal disease and VTE has received less 
research attention and requires further study. Likewise, the relationship between EI/AP 
and CHD has not been studied extensively and the inconsistent findings of previous 
studies suggest the need for further research to clarify the relationship. To our knowledge 
no studies have directly addressed the association between EI/AP and stroke, heart 
failure, or VTE. Further research is needed to identify potential relationships between 
EI/AP and these outcomes. Finally, previous studies on infection as a CVD trigger often 
only included hospitalized infections as their exposure of interest. Further, the magnitude 
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and duration of increased cardiovascular risk has varied greatly between studies and 
remains under debate. Additional research is warranted to elucidate the magnitude and 
duration of risk associated with infections across all CVD outcomes.  
 We propose to use longitudinal data from the ARIC study, the Longitudinal 
Investigation of Thromboembolism Etiology (LITE) ancillary study, the Dental-ARIC 
(D-ARIC) ancillary study, and the corresponding ARIC study participant Centers for 
Medicare and Medicaid Services (CMS) data to examine the relationship between 
periodontal disease and VTE, endodontic therapy and CVD, and infection as a trigger for 
CVD events.  We hypothesize that periodontal disease is independently associated with 
VTE, endodontic therapy is independently associated with risk of incident CVD, and 
infection is a trigger of CVD events.  The ARIC study is well-positioned to extend the 
body of research in this area because of the large number of validated CVD events, 
objective periodontal data, information on both inpatient and outpatient infections, and 
extensive data collection on potential confounders.  
 
Figure 4. Summary of dissertation papers 
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Chapter 3 – Study Design and Data Collection 
Atherosclerosis Risk in Communities (ARIC) Study 
The ARIC study is a multi-center population-based prospective cohort study 
designed to investigate the etiology and natural history of atherosclerosis in middle-aged 
Americans.158 At baseline in 1987-1989 (visit 1), 15,792 white and black men and 
women were selected from 4 US communities: Forsyth County, North Carolina; Jackson, 
Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland.158 
Subsequent exams took place during 1990 to 1992 (visit 2), 1993 to 1995 (visit 3), 1996 
to 1998 (visit 4), and 2011 to 2013 (visit 5). Visit 6 (2016-2017) is currently underway.  
Extensive information on CVD risk factors and outcomes was collected at each 
exam. Additionally, annual telephone questionnaires were administered to update 
information on CVD events and hospitalizations; phone calls have occurred semiannually 
since 2012. All hospitalizations and deaths in ARIC participants occurring through 
December 31, 2013 were identified by annual telephone follow-up call, review of 
hospital discharge lists, and death certificates. Data were abstracted from hospital and 
death records, next-of-kin interviews, and physician-completed questionnaires. CVD 
events were classified by a combination of computer algorithm and adjudicated physician 
review; disagreements were adjudicated by the ARIC Mortality and Morbidity 
Classification Committee using standardized ARIC criteria.159 A detailed discussion of 
the ARIC study design, methods, and objectives is provided elsewhere.158 
Longitudinal Investigation of Thromboembolism Etiology (LITE) 
 LITE is a prospective study of VTE occurrence in 2 pooled, multicenter, 
longitudinal population-based cohort studies: the Atherosclerosis Risk in Communities 
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(ARIC) study and the Cardiovascular Health Study (CHS).160 All possible VTE cases 
among ARIC participants occurring through December 31, 2011 were identified using 
hospital discharge codes from ARIC study participant hospitalizations. Hospital records 
were independently reviewed by two study physicians to determine the VTE case status. 
Differences were adjudicated by physician discussion. A detailed discussion of the LITE 
study design, methods, and objectives is provided elsewhere.160   
Dental ARIC (D-ARIC) 
 The purpose of D-ARIC was to determine the prevalence, extent, and severity of 
periodontal conditions in the dentate ARIC population and describe the associations 
between those conditions and prevalent CHD and atherosclerosis.48 The D-ARIC study 
was an ARIC ancillary study that took place among ARIC participants at all 4 study sites 
during visit 4 (1996-1998). All ARIC participants were screened for participation over 
the phone when they were contacted to schedule visit 4. Participants who had no natural 
teeth were not eligible to participate in D-ARIC. Additionally, participants who had 
medical contraindications to periodontal probing or who required antibiotic prophylaxis 
for periodontal probing were also excluded from the dental examination.  
D-ARIC consisted of a dental questionnaire and a dental examination adapted 
from the protocol used for the Third National Health and Nutrition Examination Survey 
(NHANES III).161 Examination components included complete soft tissue screening, 
caries status and plaque score, collection and storage of crevicular fluid, and microbial 
sampling and analysis of plaque samples. Assessments related to periodontal disease 
included the gingival index to assess inflammation, probing pocket depth around each 
tooth, cemonto-enamel junction (CEJ) to assess the distance from the CEJ to the gingival 
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margin (gingival recession), and bleeding on probing for each tooth. Attachment level 
was calculated from the sum of pocket depth and gingival recession scores.  
Dental examiners were thoroughly trained using standardized procedures to 
ensure that measurements were both valid and reliable. Further, the dental examiners 
were calibrated against a standard examiner, as well as each other to ensure consistency 
across examiners and sites. Details of the D-ARIC study objectives and methodology 
have been described in a previous publication.162 
Centers for Medicare and Medicaid Services (CMS) 
Medicare is a national social health insurance program, administered by the US 
federal government since 1966.163 Medicare coverage is available to the elderly (≥65), 
those with disability, those with end stage renal disease, and those with amyotrophic 
lateral sclerosis. The CMS Medicare data are healthcare encounter reimbursable claims 
data for individuals who are eligible for and enrolled in CMS Medicare services. The 
ARIC study has an interagency agreement with the CMS to obtain Medicare data for 
ARIC cohort participants. CMS claims for inpatient and outpatient services are available 
for eligible ARIC participants from 1991-2013. ARIC participants are matched to 
Medicare claims data based on social security number, sex, and date of birth.164 Of the 
14,899 ARIC study participants Medicare eligible in 1991, 98.7% were successfully 
matched with their Medicare beneficiary summary file. Matched participants are linked to 
inpatient, outpatient, and carrier files.  
Claims data are available for inpatient services covered under Medicare Part A 
contained in the inpatient claim file which contains final action claims data submitted by 
inpatient hospital providers for reimbursement of facility costs. Also, the MedPAR file is 
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constructed from inpatient claims and contains inpatient hospital and skilled nursing 
facility (SNF) final action stay records which summarizes all services rendered to a 
beneficiary from the time of admission to a facility through discharge. The outpatient 
claims file contains final action claims data submitted by institutional outpatient 
providers for services covered under Medicare Part B. The carrier claim file contains 
final action claims data submitted by non-institutional providers including clinicians, 
independent clinical laboratories, ambulance providers, and free-standing ambulatory 
surgical centers.  
Medicare data have a number of limitations. First, data are unavailable for ARIC 
participants who are ineligible for Medicare coverage. Medical claims data are, for the 
most part, not available for beneficiaries enrolled in managed care (HMO) organizations, 
such as Medicare Advantage insurance plans. These plans are not required to submit 
claims data for beneficiaries thus CMS files will have incomplete claims data for such 
participants.  
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Chapter 4 – Manuscript #1: Periodontal Disease and Incident Venous 
Thromboembolism: The Atherosclerosis Risk in Communities Cohort 
 
Abstract 
Background 
 Periodontal disease has been identified as a cardiovascular disease (CVD) risk factor 
but few studies have considered the relationship between periodontal disease and venous 
thromboembolism (VTE). Periodontal disease may be related to VTE through infection-
induced inflammation that contributes to platelet aggregation and hypercoagulability. We 
hypothesized that periodontal disease is independently associated with incident VTE risk. 
Methods 
 We used a prospective cohort study design using longitudinal data from the 
Atherosclerosis Risk in Communities (ARIC) study, the Longitudinal Investigation of 
Thromboembolism Etiology (LITE) ancillary study, and the Dental-ARIC (D-ARIC) 
ancillary study to study the relationship between periodontal disease and incident VTE. 
Periodontal disease was determined using self-reported tooth loss due to gum disease and 
two clinical periodontal disease classifications. Cox-proportional hazards regression 
models were used to estimate hazard ratios and 95% confidence intervals across self-
reported tooth loss due to gum disease statuses and clinical periodontal disease 
classifications. Adjusted models were constructed to include relevant confounders 
including demographic and SES factors, VTE risk factors, and dental hygiene and access 
to care variables.    
Results 
 Self-reported periodontal disease was associated with 30% higher VTE risk that 
remained significant or borderline significant after adjustment. Crude associations 
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between clinical periodontal disease classifications were attenuated with adjustment and 
were no longer significant. 
Conclusion 
 Further research is needed to determine if periodontal disease is independently 
associated with VTE risk and if periodontal prevention and treatment could reduce VTE 
risk. 
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Introduction 
 Periodontal disease is a chronic inflammatory disease caused by bacterial infection 
of the supporting tissues around the teeth.29 Periodontitis is common with 46% of US 
adults having any periodontitis and 8.9% having severe periodontitis.32 It is a significant 
contributor to tooth loss among adults in the United States.34 The primary mechanism 
linking periodontitis and venous thromboembolism (VTE) is through infection-induced 
systemic inflammation that contributes to platelet aggregation and hypercoagulability.82 
Existing studies have shown that periodontitis is associated with higher levels of systemic 
inflammatory markers including interleukin-6 (IL-6)133, C-reactive protein (CRP)133, 134, 
and soluble intercellular adhesion molecule-1 (sICAM-1).135 Higher levels of these 
inflammatory markers have also been associated with increased risk of cardiovascular 
disease (CVD) and VTE.134, 142, 165, 166 The potential pathway linking periodontal infection 
and VTE risk is presented in the causal diagram in Figure 5 below.   
 VTE, comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a 
common, life-threatening disease in the United States with over 500,000 hospitalized 
cases annually.167 The Longitudinal Investigation of Thromboembolism Etiology (LITE) 
study found an incidence rate of 1.92 per 1000 person years for VTE in a community-
based cohort of middle and older aged individuals and a 28-day case fatality rate of 
11%.168 
 Previous epidemiologic research has identified VTE risk factors including 
immobilization, surgery, trauma, cancer, older age, family history of VTE, genetics, oral 
contraceptive use, and obesity.169, 170 Though multiple individual studies and meta-
analyses have reported an association between periodontal infection and increased risk of 
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CVD,82, 83 to date only one study has explored a possible association between 
periodontitis and VTE. In that study, Sanchez-Siles et al. found that periodontitis was 
more prevalent among 97 VTE patients than in the 100 healthy controls (p<.001), thus 
supporting an association between periodontal disease and VTE risk.93  
 The prospective ARIC cohort has ancillary studies which conducted dental exams 
and validated VTE events. Using these data we examined the relationship between 
periodontal disease and risk of incident VTE.  We hypothesized that periodontal disease 
is independently associated with incident VTE risk and that the risk is graded such that 
the association between periodontal disease and VTE is highest among those with more 
severe periodontal disease.  
Methods 
LITE a prospective study of VTE occurrence in 2 pooled, multicenter, 
longitudinal population-based cohort studies: the Atherosclerosis Risk in Communities 
(ARIC) study and the Cardiovascular Health Study (CHS). The LITE study design, 
methods, and VTE incidence rates have been described in detail elsewhere.160 For these 
analyses, CHS data were excluded and only ARIC data were included due to the presence 
of dental information collected at visit 4 during the dental ancillary study (D-ARIC). The 
ARIC study is a multi-center population-based prospective cohort study designed to 
investigate the etiology and natural history of atherosclerosis in middle-aged 
Americans.158 At baseline in 1987-1989 (visit 1), 15,792 white and black men and 
women were selected from 4 US communities: Forsyth County, North Carolina; Jackson, 
Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland.158 
Subsequent exams took place during 1990 to 1992 (visit 2), 1993 to 1995 (visit 3), 1996 
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to 1998 (visit 4), 2011 to 2013 (visit 5), and 2016-2017 (visit 6 currently underway). A 
detailed discussion of the ARIC study design, methods, and objectives is provided 
elsewhere.158 
The purpose of D-ARIC was to determine the prevalence, extent, and severity of 
periodontal conditions in the dentate ARIC population and describe the association 
between those conditions and prevalent CHD and atherosclerosis.48 The D-ARIC study 
was an ARIC ancillary study that took place among ARIC participants at all study sites 
during visit 4 (1996-1998). All ARIC participants who had natural teeth and who had no 
contraindications to or required antibiotic prophylaxis for periodontal probing were 
eligible to participate in D-ARIC. Details of the D-ARIC study objectives and 
methodology have been described in a previous publication.162 
For the present analyses, we used a prospective cohort study design. Visit 4 
(1996-1998) which was attended by 11,656 participants was used as the baseline for these 
analyses. All ARIC participants who reported being edentulous at exam 4 (n=1,651) and 
those who completed the D-ARIC exam (n=6,793) were included in these analyses. 
Those of races other than black and white (27), those with prevalent VTE at baseline 
(218) as determined by self-report at study entry or adjudicated VTE events occurring 
prior to baseline (visit 4), and those taking anticoagulants at baseline (visit 4) (80) were 
excluded from these analyses leaving us with a final sample size of n=8,119.  
Periodontal Disease Ascertainment 
The exposure of interest is periodontitis and was determined using self-reported 
tooth loss due to gum disease and two clinical periodontal disease classifications. Self-
reported tooth loss due to gum disease was based on yes/no responses to the question 
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“Did you lose any teeth because of gum disease”. Clinical periodontitis was assessed 
using clinical measures collected during the D-ARIC oral examination including probing 
pocket depth and gingival recession on 6 sites for all teeth. Attachment level was 
calculated from the sum of pocket depth and gingival recession scores. The first clinical 
case definition used was the CDC Periodontal Disease Surveillance workgroup in 
collaboration with the American Academy of Periodontology (CDC/AAP) definition.39  
This 4-level definition is as follows:  
No periodontitis: Not meeting the definition of mild, moderate, or severe periodontitis 
Mild periodontitis: ≥2 interproximal (between teeth) sites with attachment loss ≥3mm, 
and ≥2 interproximal sites with probing depth ≥4 mm (not on same tooth) or one site with 
probing depth ≥5 mm  
Moderate periodontitis: ≥2 interproximal sites with attachment loss ≥4 mm (not on same 
tooth), or ≥2 interproximal sites with probing depth ≥5 mm (not on same tooth) 
Severe periodontitis: ≥ 2 interproximal sites with attachment loss ≥6 mm (not on same 
tooth) and ≥1 interproximal site with probing depth ≥5 mm  
 
 The second clinical periodontal disease classification used was the Periodontal 
Profile Class (PPC) proposed by Morelli et al.40 This uses 7 tooth-level clinical 
parameters (interproximal attachment level, probing depth, bleeding on probing, gingival 
inflammation index, plaque index, the presence/absence of full prosthetic crowns for each 
tooth, and tooth status presence) to identify seven distinct periodontal profile classes 
(PPC). 
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This 7-level definition is as follows:   
PPC-A: Health 
PPC-B: Mild Disease 
PPC-C: High Gingival Inflammation Index  
PPC-D: Tooth Loss 
PPC-E: Posterior Disease 
PPC-F: Severe tooth Loss 
PPC-G: Severe Disease 
Covariate Ascertainment 
 Demographic variables including age at visit 4, sex, race, and study center were 
assessed at baseline (visit 4) or updated from information collected at study enrollment 
(visit 1). Education (some high school or less, high school diploma, college degree or 
higher) was assessed at study entry (visit 1) while income (<$25,000/year, $25,000 – 
<$50,000/year, $50,000 – <$75,000/year, >$75,000/year) was assessed at baseline (visit 
4). Common risk factors including smoking (current, former, never), alcohol 
consumption (grams/week), BMI (Kg/M2), and statin use (yes/no) were assessed at 
baseline (visit 4). Finally, oral hygiene and access to care variables including medical 
insurance status (private insurance, Medicare/Medicaid only, none), last dental visit ( <6 
months ago, 6 months – <2 years ago, 2 – <5 years ago, >5 years ago), dental visit 
frequency (regularly, only for discomfort or repair, don’t regularly visit the dentist), and 
having a current dentist (yes/no) were collected during the dental history questionnaire 
administered at baseline (visit 4). Baseline (visit 4) C-reactive protein (CRP) levels were 
measured in 2008 on plasma frozen at −70°C from visit 4 by the immunoturbidimetric 
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assay using the Siemens (Dade Behring) BNII analyzer (Dade Behring, Deerfield, Ill), 
performed according to the manufacturer's protocol. 
Outcome Ascertainment 
 The outcome of interest was incident VTE. VTE events were defined as all PEs and 
DVTs occurring in the legs (n=755). Potential incident VTE events were identified using 
diagnosis codes (415.1x, 451, 451.1x, 451.2, 451.8x, 451.9, 453, 453.0, 453.1, 453.2, 
453.8, 453.9, 996.7x, 997.2, 999.2, 38.7), hospital records, physician and consultant 
reports, and discharge summaries according to LITE study protocol.168 Hospital records 
were independently reviewed and adjudicated by two study physicians to determine the 
VTE case status. Differences were resolved by physician discussion.168 The hospital 
admission date abstracted from the patient medical record was considered the VTE date.    
Statistical Analysis 
 Descriptive statistics were calculated for study participant characteristics at baseline 
(visit 4) by periodontal disease category. Baseline (visit 4) C-reactive protein (CRP) 
levels were compared using linear regression controlling for age, race/center, and sex. 
Means were compared using the least squares means procedure in SAS 9.3. Associations 
between self-reported periodontal disease status and clinical periodontal disease 
classifications were assessed using cross tabulations and the chi-squared test. Cox-
proportional hazards regression models were used to estimate hazard ratios and 95% 
confidence intervals across self-reported tooth loss due to gum disease statuses and 
clinical periodontal disease classifications (CDC/AAP and PPC). Those who report being 
edentulous and those with different levels of periodontal disease were compared against 
those without periodontal disease (referent). The proportional hazards assumption was 
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assessed by visual inspection of the Kaplan-Meier (KM) curves and by testing the 
interaction between periodontal disease status and follow-up time.  
 Crude (unadjusted) models and those adjusting for potential confounders were 
constructed. Covariate values were taken from assessments performed at the ARIC visit 4 
exam. Only risk factors common to both periodontal disease and VTE were considered. 
Variable selection and model construction was informed by the causal diagram presented 
in Figure 5 below. In addition to crude models, model 1 included demographic and SES 
variables including age, sex, race/center, education, and income. Model 2 added 
adjustment for relevant periodontal risk factors that are also associated with VTE 
including smoking,170, 171 alcohol consumption,172, 173 BMI,174, 175 and statin use.176, 177 
Finally, model 3 additionally included adjustment for variables related to oral hygiene 
and access to care including medical insurance status, last dental visit, dental visit 
frequency, and having a current dentist.  
 Finally, we performed a sensitivity analysis in which the association between 
periodontal disease and VTE was considered excluding participants who reported a 
history of endodontic therapy since endodontic infection may trigger a similar 
inflammatory response as periodontal infection.  
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Figure 5. Causal diagram of pathways linking periodontal infection and venous 
thromboembolism risk 
 
Follow- up time began at entry into the study (visit 4) and extended to the first outcome, 
dropping out of the study, death, or else, December 31, 2011. 
Power and Sample Size 
Since we used previously collected observational data, the sample size for these 
analyses was fixed. With a fixed sample size, the question of interest becomes what is the 
minimum detectable effect (MDE) of periodontal disease on VTE for our study. We 
focused the MDE analysis on the primary analysis using the CDC/AAP periodontal 
disease definition. Using this definition, exposure was categorized as no periodontitis, 
mild periodontitis, moderate periodontitis, severe periodontitis, and edentulous. 
Frequency of each exposure classification is found in Table 4 below.  
Table 4. Frequency of CDC/AAP periodontal disease classifications among ARIC 
participants at baseline (visit 4 – 1996-1998) 
Periodontal Disease N 
No Periodontitis 750 
Mild Periodontitis 1,976 
Moderate Periodontitis 2,708 
Severe Periodontitis 1,140 
Edentulous 1,545 
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Since each exposure classification was compared to those without periodontal 
disease, we focused our MDE analysis on comparing those with severe periodontitis to 
those without periodontitis since those with severe periodontitis make up the smallest 
exposure classifications and thus the lowest powered comparison with the largest MDE. 
Additionally, we also conducted a MDE analysis comparing edentulous participants to 
those with no periodontitis since they represented the most extreme exposure categories.  
The MDE analyses were performed using the Power and Sample Size Program.178, 
179 Our study had 1,140 participants with severe periodontitis and 1,545 participants who 
were edentulous compared to 750 participants without periodontitis approximately 6% of 
whom will experience a VTE event during follow-up. Based on these criteria, Table 5 
below contains MDE HRs for α-level (type I error rate) equal to 0.05 across levels of 
power (1-β). 
Table 5. Minimum detectable effect hazard ratios by power levels  
 Power = 80% Power = 85% Power = 90% 
Severe Periodontitis 1.56 1.60 1.66 
Edentulous 1.59 1.64 1.70 
 
By convention, we used 80% power giving us a MDE = HR = 1.56 and 1.59 for 
those with severe periodontitis and those who are edentulous compared to those with no 
periodontitis respectively. This effect size is consistent with previous studies51, 81 and 
suggests that the anticipated and meaningful effect size is detectable by our study. 
Results 
Baseline (ARIC visit 4) characteristics are provided in Tables 6, 7, and 8 for study 
participants by self-reported periodontal disease status, CDC/AAP clinical periodontal 
disease status, and PPC periodontal disease classification respectively. Across exposure 
classifications, periodontal disease was more common among males compared to females 
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and among blacks compared to whites. Periodontal disease was more common among 
those of low SES status compared to those of high SES status. Those with periodontal 
disease were more likely to be smokers compared to those without periodontal disease. 
Finally, those with periodontal disease were less likely to have medical insurance, a 
current dentist, and visit the dentist regularly. 
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Table 6. Baseline (Visit 4 – 1996-1998) characteristics of ARIC participants by self-
reported periodontal disease status 
 Tooth Loss from Gum 
Disease 
No Tooth Loss from 
Gum Disease 
Total, count (%) 1,098 (13.9) 6,784 (86.1) 
Age (years), mean ± SD 63.5 (5.7) 62.6 (5.6) 
Sex, count (%)   
   Male 492 (44.8) 3,061 (45.1) 
   Female 606 (55.2) 3,723 (54.9) 
Race, count (%)   
   White 725 (66.0) 5,484 (80.8)  
   Black 373 (34.0) 1,300 (19.2) 
Education, count (%)   
   Some High School 332 (30.3) 1,169 (17.3) 
   High School Diploma 440 (40.2) 2,911 (43.0) 
   College Degree 323 (29.5) 2,694 (37.8) 
Income, count (%)   
   <$24,999 462 (43.5) 1,846 (27.7) 
   $25,000-$50,000 357 (33.6) 2,352 (35.3) 
   $50,000-$74,999 141 (13.3) 1,263 (19.0) 
   >$75,000 83 (7.8) 1,050 (15.8) 
   Refused 20 (1.9) 148 (2.2) 
Smoker, count (%)   
   Current 246 (22.6) 916 (13.6) 
   Former 510 (46.8) 2,887 (42.8) 
   Never 333 (30.6) 2,960 (43.7) 
Statin Use, count (%)   
   No 934 (85.3) 6,077 (89.8) 
   Yes 161 (14.7) 688 (10.2) 
BMI (Kg/M2), mean ± SD 29.3 (5.7) 28.7 (5.5) 
Alcohol (g/week), mean ± SD 36.5 (86.5) 32.8 (77.8) 
Medical Care Payment, count (%)   
   Health Plan    839 (77.0) 5,919 (87.6) 
   Medicare/Medicaid Only 162 (14.9) 488 (7.2) 
   None 89 (8.2) 350 (5.2) 
Current Dentist, count (%)   
   Yes 762 (69.9) 5,654 (83.6) 
   No 328 (30.1) 1,113 (16.5) 
Last Dental Visit, count (%)   
   Within last 6 months 430 (39.5) 3,721 (54.9) 
   6 months to 2 years ago 200 (18.4) 1,517 (22.4) 
   2 to 5 years ago 173 (15.9) 664 (9.8) 
   More than 5 years ago 287 (26.3) 871 (12.9) 
When do you visit Dentist, count (%)   
   Regular Basis 438 (40.0) 4,375 (64.5) 
   Discomfort/Something Fixed 568 (51.9) 2,126 (31.4) 
   Don’t go to Dentist 78 (7.1) 217 (3.2) 
   Other 10 (0.9) 61 (0.9) 
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Table 7. Baseline (Visit 4 – 1996-1998) characteristics of ARIC participants by 
CDC/AAP periodontal disease classification 
 Healthy Mild Moderate Severe Edentulous 
Total, count (%) 750 (9.2) 1,976 (24.3) 2,708 (33.4) 1,140 (14.0) 1,545 (19.0) 
Age (years), mean ± SD 61.9 (5.5) 61.6 (5.6) 62.8 (5.6) 63.0 (5.6) 64.2 (5.6) 
Sex, count (%)      
   Male 203 (27.1) 713 (36.1) 1372 (50.7) 728 (63.9) 652 (42.2) 
   Female 547 (72.9) 1263 (63.9) 1336 (49.3) 412 (36.1) 893 (57.8) 
Race, count (%)      
   White 633 (84.4) 1541 (78.0) 2273 (83.9) 873 (76.6) 1024 (66.3) 
   Black 119 (15.6) 435 (22.0) 435 (16.1) 267 (23.4) 521 (33.7) 
Education, count (%)      
   Some High School 88 (11.8) 199 (10.1) 375 (13.9) 219 (19.2) 697 (45.2) 
   High School Diploma 368 (49.1) 798 (40.5) 1177 (43.5) 487 (42.7) 610 (39.6) 
   College Degree 293 (39.1) 975 (49.4) 1152 (42.6) 434 (38.1) 234 (15.2) 
Income, count (%)      
   <$24,999 192 (25.9) 427 (22.0) 617 (23.1) 329 (29.3) 839 (57.0) 
   $25,000-$50,000 275 (37.1) 629 (32.4) 1015 (38.0) 421 (37.5) 439 (29.8) 
   $50,000-$74,999 130 (17.5) 442 (22.8) 538 (20.2) 208 (18.5) 120 (8.2) 
   >$75,000 128 (17.3) 397 (20.5) 434 (16.3) 147 (13.1) 43 (2.9) 
   Refused 16 (2.2) 45 (2.3) 64 (2.4) 19 (1.7) 31 (2.1) 
Smoker, count (%)      
   Current 54 (7.2) 158 (8.0) 351 (13.0) 257 (22.7) 396 (26.0) 
   Former 264 (35.3) 774 (39.3) 1264 (46.9) 551 (48.6) 636 (41.7) 
   Never 431 (57.5) 1038 (52.7) 1080 (40.1) 326 (28.8) 494 (32.4) 
Statin Use, count (%)      
   No 671 (89.8) 1,793 (91.0) 2,430 (90.0) 998 (87.7) 1,329 (86.5) 
   Yes 76 (10.2) 178 (9.0) 270 (10.0) 140 (12.3) 208 (13.5) 
BMI (Kg/M2), mean ± SD 28.6 (5.8) 28.3 (5.3) 28.7 (5.2) 28.8 (5.4) 29.6 (6.2) 
Alcohol (g/week), mean ± 
SD 
21.3 (50.5) 28.9 (66.5) 37.9 (81.2) 46.8 (95.8) 25.1 (84.6) 
Care Payment, count (%)      
   Health Plan    679 (90.7) 1771 (89.9) 2434 (90.2) 982 (86.6) 1058 (69.3) 
   Medicare/Medicaid Only 41 (5.5) 104 (5.3) 144 (5.3) 82 (7.2) 321 (21.0) 
   None 29 (3.9) 95 (4.8) 122 (4.5) 70 (6.2) 147 (9.6) 
Current Dentist, count (%)      
   Yes 692 (92.6) 1811 (92.4) 2398 (89.0) 934 (82.4) 696 (46.7) 
   No 55 (7.4) 149 (7.6) 298 (11.1) 199 (17.6) 795 (53.3) 
Last Dental Visit, count (%)      
   Within last 6 months 472 (63.3) 1272 (64.7) 1674 (62.2) 661 (58.4) 138 (9.2) 
   6 months to 2 years ago 171 (22.9) 478 (24.3) 649 (24.1) 238 (21.0) 216 (14.4) 
   2 to 5 years ago 67 (9.0) 136 (6.9) 215 (8.0) 199 (10.5) 325 (21.7) 
   More than 5 years ago 36 (4.8) 80 (4.1) 153 (5.7) 113 (10.0) 817 (54.6) 
Dentist Visit, count (%)      
   Regular Basis 556 (74.5) 1539 (78.3) 1988 (73.7) 707 (62.4) 91 (6.0) 
   Discomfort/Repair 175 (23.5) 396 (20.2) 647 (24.0) 392 (34.6) 1172 (78.0) 
   Don’t go to Dentist 5 (0.7) 19 (1.0) 36 (1.3) 19 (1.7) 227 (15.1) 
   Other 10 (1.3) 11 (0.6) 26 (1.0) 16 (1.3) 12 (0.8) 
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Table 8. Baseline (Visit 4 – 1996-1998) characteristics of ARIC participants by periodontal profile class  
 A B C D E F G Edentulous 
Total, count (%) 1,803 (22.2) 1,012 (12.5) 674 (8.3) 769 (9.5) 965 (11.9) 866 (10.7) 785 (6.0) 1,545 (19.0) 
Age (years), mean ± SD 61.7 (5.5) 62.3 (5.8) 61.5 (5.5) 63.6 (5.6) 62.8 (5.6) 62.9 (5.5) 61.7 (5.8) 64.2 (5.6) 
Sex, count (%)         
   Male 609 (33.8) 542 (53.6) 300 (44.5) 347 (45.1) 535 (55.4) 378 (43.7) 305 (62.9) 652 (42.2) 
   Female 1,194 (66.2) 470 (46.4) 374 (55.5) 422 (54.9) 430 (44.6) 488 (56.4) 180 (37.1) 893 (57.8) 
Race, count (%)         
   White 1,742 (96.6) 980 (96.8) 188 (27.9) 629 (81.8) 948 (98.2) 570 (65.8) 263 (54.2) 1,024 (66.3) 
   Black 61 (3.4) 32 (3.2) 486 (72.1) 140 (18.2) 17 (1.8) 296 (34.2) 222 (45.8) 521 (33.7) 
Education, count (%)         
   Some High School 97 (5.4) 84 (8.3) 157 (23.4) 126 (16.4) 57 (5.9) 248 (28.6) 112 (23.1) 697 (45.2) 
   High School Diploma 755 (41.9) 454 (45.0) 216 (32.2) 375 (48.8) 431 (44.7) 408 (47.1) 191 (39.4) 610 (39.6) 
   College Degree 948 (52.7) 472 (46.7) 298 (44.4) 268 (34.9) 476 (49.4) 210 (24.3) 182 (37.5) 234 (15.2) 
Income, count (%)         
   <$24,999 252 (14.1) 168 (16.8) 269 (41.9) 196 (26.0) 141 (14.7) 369 (43.3) 170 (36.1) 839 (57.0) 
   $25,000-$50,000 606 (33.8) 364 (36.4) 210 (32.7) 326 (43.2) 361 (37.6) 319 (37.4) 154 (32.7) 439 (29.8) 
   $50,000-$74,999 444 (24.8) 231 (23.1) 101 (15.7) 141 (18.7) 228 (23.7) 97 (11.4) 76 (16.1) 120 (8.2) 
   >$75,000 441 (24.6) 215 (21.5) 51 (7.9) 77 (10.2) 214 (22.3) 52 (6.1) 56 (11.9) 43 (2.9) 
   Refused 49 (2.7) 23 (2.3) 11 (1.7) 14 (1.86) 17 (1.8) 15 (1.8) 15 (3.2) 31 (2.1) 
Smoker, count (%)         
   Current 123 (6.8) 64 (6.3) 85 (12.8) 125 (16.3) 161 (16.7) 187 (21.7) 75 (15.6) 396 (26.0) 
   Former 742 (41.2) 418 (41.4) 267 (40.2) 346 (45.2) 495 (51.3) 388 (45.1) 197 (41.0) 636 (41.7) 
   Never 936 (52.0) 528 (52.3) 312 (47.0) 295 (38.5) 309 (32.0) 286 (33.2) 209 (43.5) 494 (32.4) 
Statin Use, count (%)         
   No 1,624 (90.1) 901 (89.1) 611 (91.5) 683 (89.1) 862 (89.3) 768 (89.4) 443 (91.5) 1,329 (86.5) 
   Yes 178 (9.9) 110 (10.9) 57 (8.5) 84 (11.0) 103 (10.7) 91 (1036) 41 (8.5) 208 (13.5) 
BMI (Kg/M2), mean ± SD 27.4 (4.8) 28.3 (4.9) 30.3 (6.2) 28.9 (5.1) 28.2 (5.1) 29.6 (6.0) 29.5 (5.9) 29.6 (5.9) 
Alcohol (g/week), mean ± SD 35.1 (71.9) 36.4 (75.9) 22.0 (72.9) 32.4 (77.6) 52.7 (94.4) 27.6 (70.3) 29.5 (73.5) 25.1 (84.6) 
Care Payment, count (%)         
   Health Plan    1,727 (95.8) 946 (93.6) 508 (76.4) 989 (89.8) 923 (95.7) 693 (80.4) 380 (79.0) 1,058 (69.3) 
   Medicare/Medicaid Only 42 (2.3) 30 (3.0) 84 (12.6) 44 (5.7) 20 (2.1) 92 (10.7) 59 (12.3) 321 (21.0) 
   None 33 (1.8) 35 (3.5) 73 (11.0) 34 (4.4) 22 (2.3) 77 (8.9) 42 (8.7) 147 (9.6) 
Current Dentist, count (%)         
   Yes 1,750 (97.8) 949 (94.2) 506 (75.5) 706 (92.2) 928 (96.5) 657 (76.5) 339 (70.3) 696 (46.7) 
   No 39 (2.2) 59 (5.9) 164 (24.5) 60 (7.8) 34 (3.5) 202 (23.5) 143 (29.7) 795 (53.3) 
Last Dental Visit, count (%)         
   Within last 6 months 1,361 (75.9) 661 (65.6) 306 (45.7) 798 (65.2) 706 (73.3) 342 (39.8) 205 (42.8) 138 (9.2) 
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   6 months to 2 years ago 372 (20.8) 262 (26.0) 186 (27.8) 172 (22.5) 200 (20.8) 232 (27.0) 112 (23.4) 216 (14.4) 
   2 to 5 years ago 48 (2.7) 56 (5.6) 100 (15.0) 58 (7.6) 40 (4.2) 143 (16.7) 92 (19.2) 325 (21.7) 
   More than 5 years ago 12 (0.7) 28 (2.8) 77 (11.5) 36 (4.7) 17 (1.8) 142 (16.5) 70 (14.6) 817 (54.6) 
Dentist Visit, count (%)         
   Regular Basis 1,656 (92.4) 850 (84.3) 323 (48.3) 552 (72.1) 842 (87.4) 352 (41.0) 215 (44.5) 91 (6.1) 
   Discomfort/Repair 130 (7.3) 141 (14.0) 319 (47.7) 196 (25.6) 114 (11.8) 473 (55.1) 237 (49.1) 1,172 (78.0) 
   Don’t go to Dentist 1 (0.1) 6 (0.6) 19 (2.8) 8 (1.0) 1 (0.1) 20 (2.3) 24 (5.0) 227 (15.1) 
   Other 6 (0.3) 11 (1.1) 8 (1.2) 10 (1.3) 6 (0.6) 14 (1.6) 7 (1.5) 12 (0.8) 
PPC-A: Health 
PPC-B: Mild Disease 
PPC-C: High Gingival Inflammation Index  
PPC-D: Tooth Loss 
PPC-E: Posterior Disease 
PPC-F: Severe tooth Loss 
PPC-G: Severe Disease 
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Significant associations were observed between self-reported periodontal disease 
and both clinical periodontal disease definitions (p<.0001). The cross tabulations between 
exposure categories and the corresponding chi squared p-values are shown in Tables 9, 
10, and 11 below.  
Table 9. Cross tabulation between CDC/AAP periodontal disease classification and 
self-reported history of tooth loss due to gum disease of ARIC participants at 
baseline (Visit 4 – 1996-1998)  
 Self Report  
CDC/AAP No Yes P-Value 
Healthy 705 (95.0) 37 (5.0)  
<.0001 
Mild 1,863 (96.0) 78 (4.0) 
Moderate 2,406 (90.9) 241 (9.1) 
Severe 848 (77.9) 241 (22.1) 
Edentulous 962 (65.8) 601 (34.2) 
 
Table 10. Cross tabulation between periodontal profile classification and self-
reported history of tooth loss due to gum disease of ARIC participants at baseline 
(Visit 4 – 1996-1998)  
 Self-Report  
PPC No Yes P-Value 
A 1,719 (96.7) 58 (3.3) 
<.0001 
B 972 (97.5) 25 (2.5) 
C 574 (88.9) 72 (11.2) 
D 629 (84.4) 116 (15.6) 
E 855 (90.1) 94 (9.9) 
F 669 (79.4) 174 (20.6) 
G 404 (87.5) 58 (12.6) 
Edentulous 962 (65.8) 501 (34.2) 
PPC-A: Health 
PPC-B: Mild Disease 
PPC-C: High Gingival Inflammation Index  
PPC-D: Tooth Loss 
PPC-E: Posterior Disease 
PPC-F: Severe tooth Loss 
PPC-G: Severe Disease 
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Table 11. Cross tabulation between CDC/AAP periodontal disease classification and 
periodontal profile classification of ARIC participants at baseline (Visit 4 – 1996-
1998)  
PPC Healthy Mild Moderate Severe Edentulous P-Value 
A 340 (18.9) 850 (47.1) 569 (31.6) 44 (2.4) 0 (0.0) 
<.0001 
B 90 (8.9) 389 (38.4) 467 (46.2) 66 (6.5) 0 (0.0) 
C 28 (4.2) 277 (41.1) 280 (41.5) 89 (13.2) 0 (0.0) 
D 74 (9.6) 194 (25.2) 356 (46.3) 145 (18.9) 0 (0.0) 
E 0 (0.0) 49 (5.1) 557 (57.7) 359 (37.2) 0 (0.0) 
F 218 (25.2) 199 (23.0) 314 (36.3) 135 (15.6) 0 (0.0) 
G 0 (0.0) 18 (3.7) 165 (34.0) 302 (62.3) 0 (0.0) 
Edentulous 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1,545 (100.0) 
PPC-A: Health 
PPC-B: Mild Disease 
PPC-C: High Gingival Inflammation Index  
PPC-D: Tooth Loss 
PPC-E: Posterior Disease 
PPC-F: Severe tooth Loss 
PPC-G: Severe Disease 
 
 Table 12 below contains the mean baseline (visit 4) CRP levels by periodontal 
disease status. Mean CRP levels at baseline were lower among those who did not report a 
history of tooth loss due to gum disease compared to those who did (p=0.02). Among 
CDC/AAP clinical periodontal levels, only edentulous had a significantly higher baseline 
CRP level (p<0.0001). Comparing baseline CRP by PPC classifications, only 
classifications D (tooth loss) and edentulous had consistently higher mean CRP levels 
compared to lower levels of periodontal disease (p<0.05). 
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Table 12. C-reactive protein (CRP) level (mean and standard error) by periodontal 
disease status of ARIC Participants at Baseline (Visit 4 – 1996-1998)  
Periodontal Infection  Adjusted Mean (mg/L) Standard Error 
Self-Report   
No 4.57 0.12 
Yes 5.06* 0.21 
CDC/AAP   
0 4.30 0.26 
1 4.26 0.17 
2 4.22 0.16 
3 4.61 0.21 
Edentulous 5.91* 0.19 
PPC   
A 3.91 0.19 
B 3.97 0.23 
C 4.18 0.28 
D 4.94* 0.24 
E 4.03 0.24 
F 4.76 0.24 
G 4.74 0.91 
Edentulous 5.91* 0.19 
Adjusted for age, sex, and race/center 
* Statistically different than lower levels (p<0.05) 
PPC-A: Health 
PPC-B: Mild Disease 
PPC-C: High Gingival Inflammation Index  
PPC-D: Tooth Loss 
PPC-E: Posterior Disease 
PPC-F: Severe tooth Loss 
PPC-G: Severe Disease 
 
The proportional hazards assumption was assessed by visual inspection of the 
Kaplan-Meier (KM) curves contained in Figure 6 below and by testing the interaction 
between periodontal disease status and follow-up time. The KM curves revealed no 
significant departures from proportionality. Further, no significant interactions between 
exposure and follow-up time were observed (all p-values >.05).  
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Figure 6. Kaplan-Meier survival curves for incident VTE by periodontal disease 
status of ARIC Participants 
 
A. KM curve by self-reported periodontal disease  
B. KM curve by CDC/AAP clinical periodontal disease status 
C. KM curve by PPC clinical periodontal disease classification 
A  
 
B 
 
C 
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Table 13 contains the results of the Cox proportional hazards regression models. 
Self-reported tooth loss due to periodontal disease was associated with higher risk of 
VTE. This association remained significant or borderline significant after adjustment for 
potential confounders. After adjustment, self-reported tooth loss due to gum disease was 
associated with 30% higher VTE risk compared to those who did not report past tooth 
loss due to gum disease (HR = 1.3 (1.0, 1.73)). Crude associations between CDC/AAP 
and PPC periodontal disease were observed but these associations were attenuated with 
adjustment and produced no statistically significant results. 
Results from the sensitivity analysis in which we excluded participants who 
reported a history of endodontic therapy did not significantly differ from the primary 
results and are presented in Table 14 below.
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Table 13. Association (HR and 95% CI) between self-reported and clinical periodontal disease and incident VTE in the 
ARIC cohort 
 Events N Crude Model 1 Model 2 Model 3 
Self-Report       
   No 246 6,784 Ref Ref Ref Ref 
   Yes 61 1,098 1.64 (1.24, 2.17) 1.36 (1.02, 1.81) 1.30 (0.97, 1.74) 1.29 (0.96, 1.73) 
CDC/AAP       
   Healthy 31 750 Ref Ref Ref Ref 
   Mild 51 1,976 0.61 (0.39, 0.95) 0.59 (0.37, 0.93) 0.59 (0.38, 0.94) 0.60 (0.38, 0.95) 
   Moderate 103 2,708 0.93 (0.52, 1.39) 0.89 (0.59, 1.33) 0.86 (0.57, 1.29) 0.86 (0.57, 1.29) 
   Severe 41 1,140 0.92 (0.57, 1.46) 0.77 (0.48, 1.25) 0.73 (0.45, 1.18) 0.71 (0.43, 1.15) 
   Edentulous 88 1,545 1.59 (1.06, 2.39) 1.09 (0.71, 1.68) 1.00 (0.65, 1.54) 1.02 (0.63, 1.63) 
PPC       
   A 53 1,803 Ref Ref Ref Ref 
   B 34 1,012 1.16 (0.76, 1.79) 1.00 (0.64, 1.55) 0.94 (0.60, 1.46) 0.90 (0.58, 1.40) 
   C 28 674 1.45 (0.92, 2.29) 0.84 (0.49, 1.42) 0.74 (0.43, 1.25) 0.70 (0.41, 1.20) 
   D 25 769 1.15 (0.71, 1.85) 0.85 (0.52, 1.38) 0.74 (0.45, 1.21) 0.71 (0.43, 1.17) 
   E 26 965 0.95 (0.59, 1.52) 0.90 (0.56, 1.45) 0.82 (0.51, 1.33) 0.81 (0.50, 1.31) 
   F 35 866 1.46 (0.95, 2.24) 0.95 (0.60, 1.51) 0.81 (0.51, 1.29) 0.75 (0.46, 1.21) 
   G 25 485 1.90 (1.18, 3.06) 1.20 (0.71, 2.02) 1.05 (0.62, 1.77) 0.90 (0.52, 1.57) 
   Edentulous 88 1,545 2.29 (1.63, 3.22) 1.31 (0.88, 1.95) 1.09 (0.73, 1.64) 1.03 (0.64, 1.65) 
Model 1: Included age, sex, race/center, education, income 
Model 2: Added smoking, alcohol consumption, BMI, and statin use  
Model 3: Added health insurance status, last dental visit, dental visit frequency, and having a current dentist 
PPC-A: Health 
PPC-B: Mild Disease 
PPC-C: High Gingival Inflammation Index  
PPC-D: Tooth Loss 
PPC-E: Posterior Disease 
PPC-F: Severe tooth Loss 
PPC-G: Severe Disease 
  
 50 
 
Table 14. Association (HR and 95% CI) between self-reported and clinical periodontal disease and incident VTE 
excluding those with self-reported history of endodontic therapy in the ARIC cohort 
 Crude Model 1 Model 2 Model 3 
Self-Report     
   No Ref Ref Ref Ref 
   Yes 1.61 (1.16, 2.23) 1.33 (0.95, 1.86) 1.27 (0.91, 1.79) 1.26 (0.90, 1.77) 
CDC/AAP     
   Healthy Ref Ref Ref Ref 
   Mild 0.51 (0.28, 0.94) 0.49 (0.27, 0.91) 0.51 (0.28, 0.94) 0.52 (0.28, 0.96) 
   Moderate 0.99 (0.59, 1.65) 0.93 (0.55, 1.56) 0.90 (0.53, 1.51) 0.91 (0.54, 1.53) 
   Severe 0.67 (0.35, 1.26) 0.55 (0.29, 1.05) 0.51 (0.27, 0.99) 0.49 (0.25, 0.95) 
   Edentulous 1.37 (0.83, 2.26) 0.97 (0.58, 1.63) 0.89 (0.52, 1.49) 0.86 (0.49, 1.50) 
PPC     
   A Ref Ref Ref Ref 
   B 1.01 (0.54, 1.89) 1.00 (0.64, 1.55) 0.83 (0.44, 1.58) 0.80 (0.42, 1.51) 
   C 1.43 (0.79, 2.61) 0.84 (0.49, 1.42) 0.66 (0.34, 1.31) 0.59 (0.30, 1.19) 
   D 1.30 (0.67, 2.55) 0.85 (0.52, 1.38) 0.75 (0.37, 1.50) 0.69 (0.34, 1.40) 
   E 0.82 (0.45, 1.88) 0.90 (0.56, 1.45) 0.75 (0.37, 1.55) 0.74 (0.36, 1.52) 
   F 1.42 (0.82, 2.47) 0.95 (0.60, 1.51) 0.71 (0.39, 1.30) 0.62 (0.33, 1.17) 
   G 1.42 (0.74, 2.74) 1.20 (0.71, 2.02) 0.75 (0.37, 1.52) 0.62 (0.29, 1.31) 
   Edentulous 2.06 (1.31, 3.23) 1.31 (0.88, 1.95) 0.94 (0.56, 1.57) 0.79 (0.43, 1.43) 
Model 1: Included age, sex, race/center, education, income 
Model 2: Added smoking, alcohol consumption, BMI, and statin use  
Model 3: Added health insurance status, last dental visit, dental visit frequency, and having a current dentist 
PPC-A: Health 
PPC-B: Mild Disease 
PPC-C: High Gingival Inflammation Index  
PPC-D: Tooth Loss 
PPC-E: Posterior Disease 
PPC-F: Severe tooth Loss 
PPC-G: Severe Disease 
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Discussion 
 We conducted a prospective cohort study on the relationship between periodontal 
disease and incident VTE using data from ARIC and the D-ARIC and LITE ancillary 
studies. We found that self-reported tooth loss due to gum disease was associated with 
30% higher VTE risk and remained significant or borderline significant after adjustment 
for confounding. Crude associations between CDC/AAP and PPC clinical periodontal 
disease classifications were attenuated with adjustment and were no longer significant.  
 Our results differ from the previous study evaluating periodontal disease and VTE.93 
In that study, Sanchez-Siles et al. found that periodontitis was more prevalent among 97 
VTE patients than in the 100 healthy controls (p<.001). The small sample size and case-
control study design used in this study may make these results prone to bias. Our failure 
to replicate these findings suggests that further research on the association between 
periodontal disease and VTE is needed.           
 The discrepancy between our self-reported periodontal disease and clinical 
periodontal disease results is worth exploring. The mechanisms connecting infection and 
VTE may help explain the absence of an association between clinical periodontal disease 
and VTE. It is possible that the mechanisms connecting infection and VTE (inflammation 
and hypercoagulability) may operate acutely and may be less relevant with chronic 
infections like periodontal disease. Existing studies have shown that infection is 
associated with acute VTE risk but that the increase in risk decreases over time since 
infection.121 The increase in inflammation and hypercoagulability associated with 
infection may not be sustained over the course of a chronic infection like periodontal 
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disease and may explain the lack of association between clinical periodontal disease and 
VTE.  
 Self-reported tooth loss due to gum disease may indicate more severe periodontal 
disease over a longer period of time compared to the clinical disease classifications which 
were categorized based on measures taken at a single point in time. The significant 
difference in baseline CRP levels between self-reported periodontal disease 
classifications that was absent between clinical periodontal disease classifications may 
support this explanation. The potential duration and severity associated with the self-
reported exposure classification may explain the significant result that is absent in the 
clinical periodontal disease classifications.    
While studies investigating the periodontal disease treatment as a primary 
prevention strategy of CVD are lacking, a number of studies have investigated the impact 
of periodontal treatment on CVD risk factors.180 A recent meta-analysis of clinical trials 
investigating the impact of periodontal treatment on CVD risk factors found that 
periodontal treatment was effective at reducing systemic inflammatory marker levels and 
improving lipid profiles in subjects with periodontititis.151 Further research is needed to 
determine if periodontal treatment reduces VTE risk.  
  Our study has a number of strengths, including a large sample size from a 
community cohort with lengthy follow-up and rigorous methodology to adjudicate VTE 
events. It also has limitations. Since we are only assessing exposure at a single time point, 
our study could suffer from measurement error since participant’s periodontal disease 
status could change between baseline and the time of their event. Changes in periodontal 
disease status after baseline could not be accounted for and could create misclassification 
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of our exposure groups. This potential time lag between exposure and the outcome of 
interest would most likely lead to non-differential misclassification which could bias our 
results towards the null and may explain the absence of significant findings. Further, 
there could be measurement error associated with self-reported tooth loss due to gum 
disease and residual confounding due to the inability to include unmeasured confounders. 
The vast majority of VTE events were symptomatic since events were captured via 
hospital records and were clinically diagnosed and verified by the investigators without 
specific screening for asymptotic VTE events.   
Conclusion 
Self-reported tooth loss due to periodontal disease was associated with a 30% 
increase in VTE risk. The CDC/AAP and PPC clinical periodontal disease classifications 
were not associated with VTE risk. Further research is needed to elucidate the periodontal 
disease-VTE relationship.  
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Chapter 5 – Manuscript #2: Endodontic Therapy and Cardiovascular Disease: The 
Atherosclerosis Risk in Communities Cohort 
 
Abstract 
Background 
 Existing studies of an association between endodontic infection (EI) and 
cardiovascular disease (CVD) have produced mixed results. The majority of studies have 
focused the relationship between EI and coronary heart disease (CHD) while few studies 
have considered the relationship between EI and ischemic stroke (IS), heart failure (HF), 
or venous thromboembolism (VTE). EI may be related to CVD through infection-induced 
inflammation that contributes to atherosclerotic development and hypercoagulability. We 
hypothesized that EI is independently associated with CHD, IS, HF, and VTE risk. 
Methods 
 We used a prospective cohort study design using longitudinal data from the 
Atherosclerosis Risk in Communities (ARIC) study, the Longitudinal Investigation of 
Thromboembolism Etiology (LITE) ancillary study, and the Dental-ARIC (D-ARIC) 
ancillary study to study the relationship between EI and incident CHD, IS, HF, and VTE. 
In the absence of radiographic information, EI was assessed through participants’ self-
reports of past endodontic therapy (ET). Cox-proportional hazards regression models 
were used to estimate hazard ratios and 95% confidence intervals for CHD, IS, HF, and 
VTE across ET classifications. Adjusted models were constructed to include relevant 
confounders including demographic and SES factors, CVD risk factors, and dental 
hygiene and access to care variables.    
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Results 
 No significant associations between self-reported history of ET and any of our 
outcomes of interest (CHD, IS, HF, VTE) were observed after adjustment for 
confounding.  
Conclusion 
 Further research is needed to determine if EI is independently associated with CVD 
risk and if EI prevention and treatment could reduce CVD risk. 
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Introduction 
 Endodontic infection (EI) is infection of the dental root canal system in the pulp of 
the tooth and the major etiologic agent of apical periodontitis (AP) or infection of the 
apex of the tooth root.181 EI/AP is relatively common but previous estimates of 
prevalence in western countries have varied between 14% and 70%.28 A recent study 
conducted in Finland found that 27% of adults had one of more teeth with EI/AP.99 Most 
epidemiologic studies that have explored the association between dental infections and 
cardiovascular disease (CVD) have focused on periodontal disease. Overall, they have 
found positive associations between periodontal disease and CVD.82  
 The primary mechanism linking both EI/AP and periodontitis and CVD includes 
systemic inflammation that leads to both atherosclerotic development and platelet 
aggregation and hypercoagulability.82 Existing studies have shown that both EI/AP and 
periodontitis are associated with systemic inflammatory markers levels including 
interleukin-6 (IL-6)133, 182-184, C-reactive protein (CRP)133, 134, 184, and soluble intercellular 
adhesion molecule-1 (sICAM-1)135. These inflammatory markers have also been 
associated with increased risk of CVD and venous thromboembolism (VTE).134, 142, 165, 166 
The relationship between endodontic infection and CVD has not been studied as 
extensively but EI/AP may be related to CVD and VTE through these same 
mechanisms.94  
 In 2009, Caplan et al used data from the Atherosclerosis Risk in Communities study 
(ARIC) and the dental ancillary study (D-ARIC) to show a cross-sectional association 
between self-reported history of root canal therapy and prevalent CHD.94 Since then, 
several other studies evaluating EI/AP and CVD have been published with mixed 
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results.185 A recent systematic review found 19 studies that evaluated the association 
between apical periodontitis and CVD.186 While 13 of the 19 studies found a positive 
association between AP and CVD, 5 found no association and 1 study found a negative 
association.186 The authors conclude that there is considerable heterogeneity among 
previous studies in terms of study design, study population, outcomes of interest, and AP 
evaluation methods that has resulted in a lack of quality evidence of a causal 
relationship.186  
Clinically, EI/AP is diagnosed through observation of periapical bony lesions on 
radiographs (indicative of chronic endodontic inflammation) or of radiopaque material in 
the root canal system (indicative of a history of root canal therapy).94 In the absence of 
radiographic information, one way to estimate history of EI/AP is through participants’ 
self-reports of endodontic therapy (ET).  
 Few previous studies have directly addressed the association between ET and the 
longitudinal development of stroke, heart failure (HF), or VTE. Therefore, we used 
longitudinal data from ARIC and the dental ancillary study (D-ARIC) to test the 
hypothesis that ET is independently associated with risk of incident CHD, incident 
stroke, incident VTE, and incident heart failure. We further hypothesized that the 
association would be graded such that those with multiple root canals will be at highest 
risk of incident CVD/VTE events.    
Methods 
The ARIC study is a multi-center population-based prospective cohort study 
designed to investigate the etiology and natural history of atherosclerosis in middle-aged 
Americans.158 At baseline in 1987-1989 (visit 1), 15,792 white and black men and 
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women were enrolled from 4 US communities: Forsyth County, North Carolina; Jackson, 
Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland.158 
Subsequent clinic exams took place during 1990 to 1992 (visit 2), 1993 to 1995 (visit 3), 
1996 to 1998 (visit 4), 2011 to 2013 (visit 5), and 2016-2017(visit 6 currently underway) 
with continuously surveillance for CVD events. A detailed discussion of the ARIC study 
design, methods, and objectives is provided elsewhere.158 
The purpose of D-ARIC was to determine the prevalence, extent, and severity of 
periodontal conditions in the dentate ARIC population and describe the associations 
between those conditions and prevalent CHD and atherosclerosis.48 The D-ARIC study 
was an ARIC ancillary study that took place among ARIC participants at all 4 study sites 
during visit 4 (1996-1998). All ARIC participants who had natural teeth and who had no 
contraindications to or required antibiotic prophylaxis for periodontal probing were 
eligible to participate in D-ARIC. Details of the D-ARIC study objectives and 
methodology have been described in a previous publication.162 
 We used a prospective cohort study design in which visit 4 (1996-1998) served as 
the baseline for these analyses. All ARIC participants who completed the dental history 
questionnaire and who reported being edentulous at exam 4 (n=1,599) or who completed 
the D-ARIC exam (n=6,644) were included in the analysis. Those of races other than 
black and white (27) and those taking anticoagulants at baseline (visit 4) (100) were 
excluded from the analysis. Finally, those with the CVD outcome of interest at baseline 
as determined by self-report at study entry or adjudicated CVD events occurring prior to 
baseline (visit 4) were excluded from the respective analyses. Our final sample sizes after 
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exclusions were n=7,705 for CHD, n=7,026 for ischemic stroke, n=7,630 for HF, and 
n=7,925 for VTE. 
Endodontic Therapy Ascertainment 
 The exposure of interest was self-reported history of root canal therapy. Exposure 
was classified according to responses to the questions, “Have you ever had root canal 
therapy?” and “(If you have had root canal therapy), Have you had more than one?” 
Exposure was trichotomized as multiple root canals, one root canal, and no root canals 
according to question responses. 
Covariate Ascertainment 
 Demographic variables including age at visit 4, sex, race, and study center were 
assessed at baseline (visit 4) or updated from information collected at study enrollment 
(visit 1). Education (some high school or less, high school diploma, college degree or 
higher) was assessed at study entry (visit 1) while income (<$25,000/year, $25,000 – 
<$50,000/year, $50,000 – <$75,000/year, >$75,000/year) was assessed at baseline (visit 
4). Common risk factors including smoking (current, former, never), diabetes (yes/no), 
hypertension (yes/no), LDL (mg/dL), HDL (mg/dL), triglycerides (mg/dL), statin use 
(yes/no), BMI (Kg/M2),and alcohol consumption (grams/week)  were assessed at baseline 
(visit 4). Finally, oral hygiene and access to care variables including medical insurance 
status (private insurance, Medicare/Medicaid only, none), last dental visit ( <6 months 
ago, 6 months – <2 years ago, 2 – <5 years ago, >5 years ago), dental visit frequency 
(regularly, only for discomfort or repair, don’t regularly visit the dentist), and having a 
current dentist (yes/no) were collected during the dental history questionnaire 
administered at baseline (visit 4). Baseline (visit 4) C-reactive protein (CRP) levels were 
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measured in 2008 on plasma frozen at −70°C from visit 4 by the immunoturbidimetric 
assay using the Siemens (Dade Behring) BNII analyzer (Dade Behring, Deerfield, Ill), 
performed according to the manufacturer's protocol. 
 
Outcome Ascertainment 
 The outcomes of interest were incident CHD, incident ischemic stroke, incident 
heart failure, and incident VTE. Each outcome was analyzed separately. The methods 
used for ascertainment of outcomes included: (1) participants were contacted annually by 
phone and interviewed about interim hospitalizations; (2) local hospitals provided lists of 
hospital discharges with cardiovascular diagnoses, and these were reviewed to identify 
cohort hospitalizations; and (3) health department death certificate files were regularly 
surveyed. All discharge codes for cohort hospitalizations and listed causes of death from 
death certificates were recorded. CVD events were classified by a combination of 
computer algorithm and adjudicated physician review; disagreements were adjudicated 
by the ARIC Mortality and Morbidity Classification Committee using standardized ARIC 
criteria.159 
 Incident CHD was defined as confirmed CHD death, and fatal and nonfatal 
myocardial infarction (MI).187 Incident ischemic stroke was identified and classified as 
thrombotic or cardioembolic stroke based on discharge codes, signs, symptoms, 
neuroimaging (computerized tomography/magnetic resonance imaging), and other 
diagnostic reports.188 Both CHD and stroke events were validated by study physician 
review.  
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 Incident heart failure (HF) was defined as the first occurrence of either (1) a 
hospitalization which included an International Classification of Diseases, 9th revision, 
discharge code of 428 (428.0 to 428.9) in any position, or (2) a death certificate with a 
428 (HF) or ICD-10 code I50 (HF) in any position and was not adjudicated by physician 
review.189  
 Incident VTE was defined as all PEs and DVTs occurring in the legs and was 
identified using diagnosis codes, hospital records, physician and consultant reports, and 
discharge summaries and was validated according to LITE study protocol.168 VTE events 
were validated by LITE study physician review. 
Statistical Analysis 
 Descriptive statistics were calculated for study participant characteristics at baseline 
(visit 4) by endodontic therapy (ET) status. Baseline (visit 4) C-reactive protein (CRP) 
levels by ET status were compared using linear regression controlling for age, 
race/center, and sex. Means were compared using the least squares means procedure in 
SAS 9.3. Each outcome of interest was analyzed separately using Cox-proportional 
hazards regression models to estimate hazard ratios and 95% confidence intervals 
between ET categories. Those who reported having had a single root canal therapy and 
those having had multiple root canal therapies were compared against those without prior 
root canal therapy (referent). The proportional hazards assumption was assessed by visual 
inspection of the Kaplan-Meier (KM) survival curves and by testing the interaction 
between root canal therapy status and follow-up time.  
 Crude (unadjusted) models and those adjusting for potential confounders were 
constructed. Covariate values were taken from assessments performed at the ARIC visit 4 
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exam. Only risk factors common to both oral infection and CVD were considered. 
Variable selection and model construction was informed by the causal diagram presented 
in Figure 7 below. In addition to crude models, model 1 included demographic and SES 
variables including age, sex, race/center, education, and income. Model 2 added 
adjustment for relevant oral infection risk factors that are also associated with CVD 
including smoking,170, 171, 190, 191 alcohol consumption,172, 173, 191 BMI,174, 175, 191 statin 
use,176, 177, 191, 192 diabetes,191, 193 hypertension,191, 193, 194  LDL,151, 191, 192, 195 HDL,151, 191, 
192, 195 and triglycerides.151, 191, 192, 195 Hypertension, diabetes, LDL, HDL, and 
triglycerides were excluded from the VTE analysis due to the lack of an independent 
association between these factors and VTE.170 Finally, model 3 additionally included 
adjustment for variables related to oral hygiene and access to care including medical 
insurance status, last dentist visit, dental visit frequency, and having a current dentist.  
 Those who reported never having had ET consist of two highly disparate subgroups: 
those who had good oral health and never needed a root canal and those who had poor 
oral health and needed root canals but never received them. Since number of teeth is a 
good proxy for historical access to dental care, we conducted analyses stratified by the 
median number of teeth (24) similar to the approach used by Caplan et al.94 This allowed 
us to evaluate the potential impact of ET among those with 25 or more teeth who likely 
had access to care and received root canal therapy when needed.  
 Finally, we performed a sensitivity analysis in which the association between ET and 
CVD was considered excluding participants who reported a history of tooth loss due to 
gum disease since periodontal infection may trigger a similar inflammatory response as 
endodontic infection.  
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Figure 7. Causal diagram of pathways linking endodontic infection and 
cardiovascular disease and venous thromboembolism risk 
 
Follow- up time began at entry into the study (visit 4) and extended to the first outcome, 
dropping out of the study, death, or else, December 31, 2013 for CHD, stroke, and HF 
and December 31, 2011 for VTE. 
Power and Sample Size 
These analyses were conducted using previously collected observational data for 
which the sample size is fixed. With a fixed sample size, the question of interest became 
what is the minimum detectable effect (MDE) of ET on CVD for our study. Since the 
study considered multiple outcomes including CHD, ischemic stroke, heart failure, and 
VTE, we focused the MDE analysis on the VTE analysis since VTE is the rarest outcome 
of interest. The exposure of interest was ET categorized as no ET, 1 ET, and >1 ET. 
Since our primary analysis was stratified by median number of teeth (24), we considered 
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the MDE of the stratified analysis. The frequency of each exposure classification by teeth 
strata is found in Table 15 below.  
Table 15. Frequency of endodontic therapy classifications at baseline by number of 
teeth strata 
Endodontic Therapy <25 Teeth (N) ≥25 Teeth (N) 
0 3,128 1,474 
1 686 732 
≥2 990 915 
 
Since those with multiple ETs and those with a single ET were compared to those 
without previous ET, we focused our MDE analysis on participants with ≥25 teeth 
comparing those with a single ET and to those without a previous ET since those with a 
single ET made up the smallest exposure classification and thus the lowest powered 
comparison with the largest MDE. We also compared those with multiple ETs to those 
without previous ET since they represented the most extreme exposure categories.   
The MDE analyses were performed using the Power and Sample Size Program.178, 
179 Our study had 732 participants with a single ET and 915 participants with multiple 
ETs compared to 1,474 participants without a previous ET approximately 6% of whom 
will experience a VTE event during follow-up. Based on these criteria, Table 16 below 
contains MDE HRs for α-level (type I error rate) equal to 0.05 across levels of power (1-
β). 
  
Table 16. Minimum detect effects (HRs) of endodontic therapy on VTE by power 
levels:  
ET Power = 80% Power = 85% Power = 90% 
1 1.54 1.58 1.64 
≥2 1.48 1.51 1.56 
 
By convention, we used 80% power, giving us a MDE = HR = 1.54 and 1.48 for 
those with a single ET and those with multiple ETs compared to those without a previous 
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ET respectively. This effect size is consistent with previous studies51, 81 and suggests that 
the anticipated and meaningful effect size is detectable by our study. 
 
Results 
 
Baseline (ARIC visit 4) characteristics are provided in Table 17 below for study 
participants by self-reported ET status. In general, ET was more common among whites 
compared to blacks and among those of high SES status compared to those of low SES 
status. Those with past ET were less likely to be smokers and have diabetes compared to 
those without a history of ET. Finally, those with past ET were more likely to have 
medical insurance, a current dentist, and visit the dentist regularly. 
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Table 17. Baseline (visit 4 – 1996-1998) characteristics of ARIC participants by 
endodontic therapy status 
 Root Canal Therapy 
 None 1 Treatment ≥ 2 Treatments 
Total, count (%) 4,728 1,442 1,946 
Age (years), mean ± SD 62.9 (5.7) 62.7 (5.7) 62.4 (5.4) 
Sex, count (%)    
   Male 2,101 (44.4) 626 (43.4) 916 (47.1) 
   Female 2,627 (55.6) 816 (56.6) 1,030 (52.9) 
Race, count (%)    
   White 3,322 (70.3) 1,263 (87.6) 1,775 (91.2) 
   Black 1,406 (29.7) 179 (12.4) 171 (8.8) 
Education, count (%)    
   Some High School 1,312 (27.8) 132 (9.2) 136 (7.0) 
   High School Diploma 1,981 (42.0) 637 (44.2) 829 (42.7) 
   Bachelor’s or Graduate Degree 1,428 (30.3) 673 (46.7) 975 (50.3) 
Income, count (%)    
   <$24,999 1,815 (39.6) 282 (19.8) 318 (16.5) 
   $25,000-$50,000 1,493 (32.5) 537 (37.7) 747 (38.7) 
   $50,000-$74,999 690 (15.0) 322 (22.6) 417 (21.6) 
   >$75,000 478 (10.4) 256 (17.9) 415 (21.5) 
   Refused 112 (2.4) 27 (1.9) 34 (1.8) 
Smoker, count (%)    
   Current 790 (16.8) 175 (12.2) 249 (12.8) 
   Former 1,919 (40.9) 627 (43.6) 950 (48.9) 
   Never 1,984 (42.3) 636 (44.2) 743 (38.3) 
Diabetes mellitus, count (%)    
   No 3,768 (80.4) 1,262 (88.1) 1,697 (87.7) 
   Yes 917 (19.6) 170 (11.9) 239 (12.4) 
Hypertension, count (%)    
   No 2,774 (59.0) 962 (66.9) 1,330 (68.5) 
   Yes 1,927 (41.0) 476 (33.1) 611 (31.5) 
LDL (mg/dL), mean ± SD 3.20 (0.97) 3.15 (0.85) 3.14 (0.82) 
HDL (mg/dL), mean ± SD 1.28 (0.42) 1.33 (0.45) 1.28 (0.47) 
Triglycerides (mg/dL), mean ± SD 1.61 (0.98) 1.62 (0.93) 1.67 (1.01) 
Statin Use, count (%)    
   No 4,197 (89.2) 1,288 (89.4) 1,716 (88.2) 
   Yes 511 (10.9) 152 (10.6) 229 (11.8) 
BMI (Kg/M2), mean ± SD 29.1 (5.9) 28.1 (5.0) 28.4 (5.1) 
Alcohol (g/week), mean ± SD 28.9 (76.0) 38.8 (83.1) 38.2 (82.4) 
Care Payment, count (%)    
   Health Plan    3,769 (80.1) 1,345 (93.5) 1,826 (93.9) 
   Medicare/Medicaid Only 564 (12.0) 56 (3.9) 64 (3.3) 
   None 369 (7.9) 37 (2.6) 54 (2.9) 
Current Dentist, count (%)    
   Yes 3,380 (71.8) 1,352 (94.0) 1,829 (94.2) 
   No 1,330 (28.2) 87 (6.1) 112 (5.8) 
Last Dental Visit, count (%)    
   Within last 6 months 1,131 (24.0) 50 (3.5) 53 (2.7) 
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   6 months to 2 years ago 679 (14.4) 87 (6.0) 101 (5.2) 
   2 to 5 years ago 1,003 (21.3) 339 (23.5) 423 (21.8) 
   More than 5 years ago 1,897 (40.3) 964 (66.9) 1,368 (70.3) 
Dental Visit, count (%)    
   Regular Basis 2,159 (45.7) 1,156 (80.2) 1,574 (80.9) 
   Discomfort/Something Fixed 2,217 (46.9) 268 (18.6) 345 (17.7) 
   Don’t go to Dentist 293 (6.2) 9 (0.6) 14 (0.7) 
   Other 54 (1.1) 8 (0.6) 12 (0.6) 
 
 Table 18 below contains the mean baseline (visit 4) CRP levels by ET status overall 
and stratified by the median number of teeth. No significant differences were present in 
mean CRP levels at baseline between ET categories (p > 0.05). 
Table 18. C-reactive protein (CRP) level (mean and standard error) by endodontic 
therapy status overall, and stratified by number of teeth of ARIC participants at 
baseline (visit 4 – 1996-1998)  
Endodontic Therapy Adjusted* Mean (mg/L) Standard Error 
All Participants   
None 4.74 0.13 
1 Treatment  4.51 0.20 
≥ 2 Treatments 4.48 018 
≥ 25 Teeth   
None 3.78 0.23 
1 Treatment 3.95 0.28 
≥ 2 Treatments  3.81 0.27 
≤ 24 Teeth   
None 5.09 0.17 
1 Treatment 4.79 0.29 
≥ 2 Treatments  4.77 0.26 
* Adjusted for age, sex, and race/center 
The proportional hazards assumption was assessed by visual inspection of the 
Kaplan-Meier (KM) curves contained in Figure 8 below and by testing the interaction 
between periodontal disease status and follow-up time. The KM curves revealed no 
significant departures from proportionality. Further, no significant interactions between 
endodontic therapy status and follow-up time were observed (all p-values > 0.05).  
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Figure 8. Kaplan-Meier survival curves for incident CHD, ischemic stroke, heart failure, and VTE by endodontic 
therapy status among ARIC participants 
A 
 
B 
 
C 
 
D 
 
A - CHD 
B - Stroke 
C - HF 
D – VTE 
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Table 19 contains the results of the Cox proportional hazards regression models 
for ET and CHD. Crude models for all participants showed that those with a single ET 
and those with multiple ETs had lower CHD risk that was attenuated with adjustment for 
confounders and was no longer statistically significant. Among those with more than 24 
teeth, both single ET (HR = 1.1 (0.7, 1.6)) and multiple ETs (HR = 1.1 (0.8, 1.6)) were 
associated with higher CHD risk after adjustment for confounding but these associations 
failed to reach statistical significance. 
Ischemic stroke results are found in Table 20 below. Crude models from the 
combined analysis showed lower stroke risk among both those with a single ET and those 
with multiple ETs that was attenuated with adjustment for confounders and was no longer 
significant. In the stratified analysis, among those with more than 24 teeth, no 
associations between single ET (HR = 0.9 (0.6, 1.5) and multiple ETs (HR = 0.9 (0.5, 
1.4)) and ischemic stroke were observed.  
Table 21 contains the results of the Cox proportional hazards regression models 
for ET and HF. The crude models from the unstratified analysis showed that ET was 
associated with lower HF risk that was attenuated with adjustment for confounders and 
was no longer statistically significant. Among those with more than 24 teeth, both crude 
and adjusted models showed no association between ET and HF for both single ET (HR 
= 0.8 (0.6, 1.1)) and multiple ETs (HR = 0.8 (0.6, 1.1). 
Table 22 contains the Cox proportional hazards regression model results for ET 
and VTE. In the crude models, ET was associated with lower VTE risk that was 
attenuated with adjustment and was no longer significant. The stratified analysis showed 
that the multiple ETs category was associated with higher VTE risk in those with more 
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than 24 teeth (HR = 1.2 (0.6, 1.6) but this association failed to reach statistical 
significance.    
Results from the sensitivity analysis in which we excluded participants who 
reported a history of tooth loss due to gum disease did not significantly differ from the 
primary results and are presented in Tables 23-26 below.
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Table 19. Association (hazard ratio and 95% confidence interval) between self-reported endodontic therapy and 
incident coronary heart disease in the ARIC cohort, overall and stratified by the median number of teeth  
Endodontic 
Therapy 
Events N  Crude Model Model 1 Model 2 Model 3 
None 446 4,452 Ref Ref Ref Ref 
1 Treatment 105 1,397 0.71 (0.57, 0.88) 0.85 (0.68, 1.06) 0.96 (0.76, 1.20) 1.01 (0.80, 1.28) 
≥ 2 Treatments  154 1,856 0.79 (0.66, 0.95) 0.97 (0.80, 1.18) 1.07 (0.87, 1.31) 1.11 (0.90, 1.37) 
≥ 25 Teeth       
None 91 1,457 Ref Ref Ref Ref 
1 Treatment 43 729 0.94 (0.66, 1.36) 0.99 (0.69, 1.43) 1.09 (0.74, 1.58) 1.06 (0.73, 1.55) 
≥ 2 Treatments  57 891 1.01 (0.72, 1.40) 1.09 (0.78, 1.53) 1.10 (0.77, 1.56) 1.09 (0.77, 1.55) 
≤ 24 Teeth       
None 355 2,995 Ref Ref Ref Ref 
1 Treatment 62 668 0.73 (0.56, 0.95) 0.79 (0.59, 1.05) 0.89 (0.66, 1.18) 0.97 (0.72, 1.31) 
≥ 2 Treatments  97 965 0.81 (0.64, 1.01) 0.87 (0.68, 1.12) 1.02 (0.79, 1.31) 1.08 (0.83, 1.42) 
Model 1 Included age, sex, race/center, education, and income 
Model 2 Added smoking, diabetes, alcohol consumption, BMI, hypertension, LDL, HDL, triglycerides, statin use 
Model 3 Added usual medical care payment mechanism, last dental visit, dental visit frequency, and having a current dentist 
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Table 20. Association (hazard ratio and 95% confidence interval) between self-reported endodontic therapy and 
incident ischemic stroke in the ARIC cohort, overall and stratified by the median number of teeth  
Endodontic 
Therapy 
Events N Crude Model Model 1 Model 2 Model 3 
None 292 4,598 Ref Ref Ref Ref 
1 Treatment 58 1,417 0.60 (0.46, 0.80) 0.76 (0.57, 1.02) 0.80 (0.59, 1.08) 0.83 (0.61, 1.14) 
≥ 2 Treatments 75 1,911 0.58 (0.45, 0.75) 0.78 (0.59, 1.02) 0.82 (0.62, 1.08) 0.84 (0.63, 1.12) 
≥ 25 Teeth       
0 ET 59 1,466 Ref Ref Ref Ref 
1 ET 23 734 0.77 (0.48, 1.25) 0.82 (0.51, 1.34) 0.90 (0.54, 1.49) 0.91 (0.55, 1.52) 
≥ 2 ET 28 913 0.75 (0.48, 1.17) 0.83 (0.53, 1.32) 0.87 (0.54, 1.39) 0.85 (0.53, 1.37) 
≤ 24 Teeth       
0 ET 233 3,132 Ref Ref Ref Ref 
1 ET 35 683 0.63 (0.45, 0.91) 0.75 (0.52, 1.09) 0.76 (0.53, 1.14) 0.80 (0.54, 1.19) 
≥ 2 ET 47 998 0.60 (0.44, 0.81) 0.73 (0.52, 1.02) 0.77 (0.54, 1.09) 0.80 (0.56, 1.15) 
Model 1 Included age, sex, race/center, education, and income 
Model 2 Added smoking, diabetes, alcohol consumption, BMI, hypertension, LDL, HDL, triglycerides, statin use 
Model 3 Added usual medical care payment mechanism, last dental visit, dental visit frequency, and having a current dentist 
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Table 21. Association (hazard ratio and 95% confidence interval) between self-reported endodontic therapy and 
incident heart failure in the ARIC cohort, overall and stratified by the median number of teeth  
Endodontic 
Therapy 
Events N Crude Model Model 1 Model 2 Model 3 
None 740 4,406 Ref Ref Ref Ref 
1 Treatment 150 1,376 0.60 (0.51, 0.72) 0.77 (0.64, 0.93) 0.85 (0.70, 1.02) 0.93 (0.77, 1.13) 
≥ 2 Treatments 217 1,848 0.65 (0.56, 0.76) 0.89 (0.77, 1.05) 0.92 (0.77, 1.09) 1.01 (0.85, 1.21) 
≥ 25 Teeth       
None 145 1,444 Ref Ref Ref Ref 
1 Treatment 54 718 0.75 (0.55, 1.02) 0.78 (0.57, 1.07) 0.79 (0.57, 1.09) 0.79 (0.58, 1.10) 
≥ 2 Treatments 67 885 0.73 (0.55, 0.98) 0.81 (0.60, 1.09) 0.78 (0.57, 1.06) 0.79 (0.58, 1.07) 
≤ 24 Teeth       
None 595 2,962 Ref Ref Ref Ref 
1 Treatment 96 658 0.66 (0.53, 0.82) 0.80 (0.64, 1.01) 0.87 (0.69, 1.10) 0.99 (0.77, 1.27) 
≥ 2 Treatments 150 963 0.72 (0.60, 0.86) 0.94 (0.77, 1.14) 1.00 (0.81, 1.22) 1.14 (0.91, 1.41) 
Model 1 Included age, sex, race/center, education, and income 
Model 2 Added smoking, diabetes, alcohol consumption, BMI, hypertension, LDL, HDL, triglycerides, statin use 
Model 3 Added usual medical care payment mechanism, last dental visit, dental visit frequency, and having a current dentist 
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Table 22. Association (hazard ratio and 95% confidence interval) between self-reported endodontic therapy and 
incident venous thromboembolism in the ARIC cohort, overall and stratified by the median number of teeth  
Endodontic 
Therapy 
Events N Crude Model Model 1 Model 2 Model 3 
None 203 4,602 Ref Ref Ref Ref 
1 Treatment 46 1,418 0.69 (0.50, 0.95) 0.83 (0.59, 1.17) 0.86 (0.61, 1.21) 0.90 (0.64, 1.28) 
≥ 2 Treatments 56 1,905 0.63 (0.47, 0.85) 0.85 (0.62, 1.17) 0.87 (0.63, 1.20) 0.92 (0.66, 1.27) 
≥ 25 Teeth       
None 47 1,474 Ref Ref Ref Ref 
1 Treatment 19 732 0.81 (0.47, 1.37) 0.83 (0.49, 1.43) 0.85 (0.49, 1.45) 0.86 (0.50, 1.48) 
≥ 2 Treatments 31 915 1.05 (0.67, 1.65) 1.12 (0.71, 1.79) 1.17 (0.73, 1.87) 1.20 (0.75, 1.92) 
≤ 24 Teeth       
None 156 3,128 Ref Ref Ref Ref 
1 Treatment 27 686 0.73 (0.48, 1.09) 0.86 (0.56, 1.34) 0.91 (0.58, 1.41) 1.00 (0.63, 1.56) 
≥ 2 Treatments 25 990 0.48 (0.31, 0.72) 0.68 (0.43, 1.07) 0.70 (0.45, 1.11) 0.79 (0.50, 1.26) 
Model 1 Included age, sex, race/center, education, income 
Model 2 Added smoking, alcohol consumption, BMI, statin use  
Model 3 Added usual medical care payment mechanism, last dental visit, dental visit frequency, and having a current dentist 
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Table 23. Association (hazard ratio and 95% confidence Interval) between self-reported endodontic therapy and 
incident coronary heart disease in the ARIC cohort excluding participants who self-reported tooth loss due to gum 
disease, overall and stratified by median number of teeth  
Endodontic 
Therapy 
Crude Model Model 1 Model 2 Model 3 
None Ref Ref Ref Ref 
1 Treatment 0.73 (0.58, 0.92) 0.86 (0.68, 1.09) 0.98 (0.76, 1.25) 1.03 (0.80, 1.33) 
≥ 2 Treatments  0.81 (0.66, 0.99) 0.99 (0.80, 1.23) 1.08 (0.87, 1.35) 1.13 (0.90, 1.43) 
≥ 25 Teeth     
None Ref Ref Ref Ref 
1 Treatment 0.91 (0.62, 1.33) 0.94 (0.64, 1.37) 1.01 (0.68, 1.50) 1.00 (0.67, 1.48) 
≥ 2 Treatments  0.97 (0.69, 1.37) 1.04 (0.73, 1.48) 1.04 (0.72, 1.50) 1.04 (0.72, 1.50) 
≤ 24 Teeth     
None Ref Ref Ref Ref 
1 Treatment 0.75 (0.56, 1.02) 0.83 (0.61, 1.14) 0.96 (0.70, 1.32) 1.05 (0.75, 1.47) 
≥ 2 Treatments  0.84 (0.65, 1.08) 0.93 (0.70, 1.22) 1.08 (0.82, 1.44) 1.17 (0.87, 1.58) 
Model 1 Included age, sex, race/center, education, and income 
Model 2 Added smoking, diabetes, alcohol consumption, BMI, hypertension, LDL, HDL, triglycerides, statin use 
Model 3 Added usual medical care payment mechanism, last dental visit, dental visit frequency, and having a current dentist 
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Table 24. Association (hazard ratio and 95% confidence Interval) between self-reported endodontic therapy and 
incident ischemic stroke in the ARIC cohort excluding participants who self-reported tooth loss due to gum disease, 
overall and stratified by median number of teeth  
Endodontic 
Therapy 
Crude Model Model 1 Model 2 Model 3 
None Ref Ref Ref Ref 
1 Treatment 0.61 (0.45, 0.83) 0.78 (0.57, 1.07) 0.82 (0.59, 1.14) 0.88 (0.63, 1.23) 
≥ 2 Treatments  0.63 (0.48, 0.82) 0.84 (0.63, 1.11) 0.89 (0.66, 1.19) 0.93 (0.69, 1.27) 
≥ 25 Teeth     
None Ref Ref Ref Ref 
1 Treatment 0.79 (0.48, 1.30) 0.83 (0.51, 1.38) 0.91 (0.54, 1.53) 0.93 (0.55, 1.57) 
≥ 2 Treatments  0.80 (0.51, 1.26) 0.89 (0.56, 1.42) 0.94 (0.59, 1.52) 0.92 (0.57, 1.50) 
≤ 24 Teeth     
None Ref Ref Ref Ref 
1 Treatment 0.63 (0.43, 0.94) 0.76 (0.51, 1.15) 0.79 (0.51, 1.20) 0.86 (0.55, 1.33) 
≥ 2 Treatments  0.63 (0.45, 0.88) 0.78 (0.54, 1.12) 0.82 (0.56, 1.20) 0.90 (0.61, 1.33) 
Model 1 Included age, sex, race/center, education, and income 
Model 2 Added smoking, diabetes, alcohol consumption, BMI, hypertension, LDL, HDL, triglycerides, statin use 
Model 3 Added usual medical care payment mechanism, last dental visit, dental visit frequency, and having a current dentist 
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Table 25. Association (hazard ratio and 95% confidence Interval) between self-reported endodontic therapy and 
incident heart failure in the ARIC cohort excluding participants who self-reported tooth loss due to gum disease, 
overall and stratified by median number of teeth  
Endodontic 
Therapy 
Crude Model Model 1 Model 2 Model 3 
None Ref Ref Ref Ref 
1 Treatment 0.59 (0.49, 0.72) 0.75 (0.62, 0.92) 0.81 (0.66, 1.00) 0.89 (0.72, 1.10) 
≥ 2 Treatments  0.65 (0.55, 0.77) 0.88 (0.73, 1.05) 0.89 (0.74, 1.07) 0.97 (0.80, 1.18) 
≥ 25 Teeth     
None Ref Ref Ref Ref 
1 Treatment 0.76 (0.55, 1.05) 0.77 (0.56, 1.07) 0.78 (0.56, 1.09) 0.79 (0.56, 1.09) 
≥ 2 Treatments  0.74 (0.55, 1.00) 0.80 (0.59, 1.09) 0.78 (0.57, 1.08) 0.79 (0.58, 1.09) 
≤ 24 Teeth     
None Ref Ref Ref Ref 
1 Treatment 0.62 (0.48, 0.79) 0.78 (0.60, 1.01) 0.83 (0.63, 1.09) 0.93 (0.70, 1.24) 
≥ 2 Treatments  0.70 (0.57, 0.86) 0.93 (0.74, 1.16) 0.97 (0.76, 1.22) 1.11 (0.86, 1.42) 
Model 1 Included age, sex, race/center, education, and income 
Model 2 Added smoking, diabetes, alcohol consumption, BMI, hypertension, LDL, HDL, triglycerides, statin use 
Model 3 Added usual medical care payment mechanism, last dental visit, dental visit frequency, and having a current dentist 
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Table 26. Association (hazard ratio and 95% confidence Interval) between self-reported endodontic therapy and 
incident venous thromboembolism in the ARIC cohort excluding participants who self-reported tooth loss due to gum 
disease, overall and stratified by median number of teeth  
Endodontic 
Therapy 
Crude Model Model 1 Model 2 Model 3 
None Ref Ref Ref Ref 
1 Treatment 0.72 (0.51, 1.02) 0.87 (0.60, 1.26) 0.89 (0.62, 1.29) 0.92 (0.63, 1.34) 
≥ 2 Treatments 0.66 (0.48, 0.91) 0.88 (0.62, 1.24) 0.89 (0.63, 1.26) 0.92 (0.64, 1.31) 
≥ 25 Teeth     
None Ref Ref Ref Ref 
1 Treatment 0.83 (0.48, 1.41) 0.84 (0.49, 1.44) 0.85 (0.49, 1.46) 0.87 (0.51, 1.50) 
≥ 2 Treatments 0.96 (0.60, 1.54) 1.02 (0.63, 1.64) 1.05 (0.65, 1.70) 1.08 (0.67, 1.76) 
≤ 24 Teeth     
None Ref Ref Ref Ref 
1 Treatment 0.72 (0.45, 1.16) 0.93 (0.56, 1.55) 0.96 (0.58, 1.59) 1.05 (0.62, 1.77) 
≥ 2 Treatments 0.50 (0.31, 0.81) 0.77 (0.46, 1.29) 0.79 (0.47, 1.32) 0.87 (0.51, 1.48) 
Model 1 Included age, sex, race/center, education, income 
Model 2 Added smoking, alcohol consumption, BMI, statin use  
Model 3 Added usual medical care payment mechanism, last dental visit, dental visit frequency, and having a current dentist 
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Discussion 
 We conducted a prospective cohort study on the relationship between self-reported 
history of endodontic therapy and incident CHD, incident stroke, incident HF, and 
incident VTE using data from ARIC and the D-ARIC and LITE ancillary studies. We 
found no association between self-reported history of ET and any of our outcomes of 
interest that remained after adjustment for confounding in either the overall analysis or 
among those with more than 24 teeth in the stratified analysis. Our results differ from the 
previous studies that identified a positive association between EI/AP and CHD94, 101-103, 
107-110 but are consistent with other previous studies that found no association between 
EI/AP and CHD.47, 111  
 The discrepancy between our results and the majority of previous studies is worth 
exploring. We hypothesized an independent association between EI/AP and CVD. This 
hypothesis was based upon previous research linking EI/AP to CHD and previous studies 
that identified an association between periodontal infection and CVD through 
mechanisms that may also operate between EI/AP and CVD. The absence of an 
association ET and our CVD outcomes of interest may suggest that despite the 
similarities between EI/AP and periodontal disease, they may impact the cardiovascular 
system differently.     
In 2009, Caplan et al conducted a cross-sectional study using ARIC data and 
found that among participants with 25 or more teeth, those reporting having had ET two 
or more times had 1.62 times higher odds of CHD compared with those reporting never 
having had ET.94 This and other previous studies that used cross-sectional and case-
control study designs to identify associations between EI/AP and CHD cannot assess the 
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temporality between EI/AP and CHD and may be more prone to bias such as reverse 
causation not present in our longitudinal study.  
Previous cohort studies on EI/AP and CHD have found mixed results. Gomes et al 
found an association between endodontic burden and cardiovascular events ((RR = 1.77, 
95% CI = 1.04-3.02) but found no association between apical periodontitis, root canal 
therapy, or oral inflammatory burden and incident cardiovascular events.102 An earlier 
study by Caplan et al found that among those ≤ 40 years old, endodontic lesions were 
significantly associated with incident CHD (p < 0.05) but found no association among 
those > 40 years old.107A study from 2001 by Jansson et al found that apical lesions were 
significantly associated with death due to CVD (p<0.05) however, only age and gender 
were included in the adjusted models.196     
 Our study has a number of other strengths including a large sample size from a 
community cohort with lengthy follow-up and rigorous methodology to adjudicate CVD 
events. Our study also has a number of potential limitations that could result in failing to 
detect a potential association between EI/AP and CVD. Our study could be susceptible to 
measurement error since EI/AP exposure was assessed using self-reported ET at a single 
point in time (baseline) as a proxy for EI/AP. ET could be performed for restorative 
reasons such as prophylaxis in trauma cases and not endodontic reasons. Also, a lack of 
ET does not necessarily imply the absence of EI/AP since teeth could be extracted or 
remain asymptomatic. The lack of significant differences in baseline CRP levels between 
ET classifications may support this explanation. Since exposure was only assessed at a 
single point in time, ET that occurred during follow up was not accounted for and could 
create misclassification of our exposure groups. A potential time lag between exposure 
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and our outcomes of interest may result in non-differential misclassification which could 
bias our results towards to null. Misclassification of exposure could take place since 
historical ET may be forgotten or mistaken for other procedures.  
Two studies have evaluated the validity of self-reported history of ET compared 
to radiographic verified ET. Pitiphat et al. compared self-reported measures of ET 
obtained by a self-administered questionnaire with measures simultaneously obtained 
with clinical and radiograph examinations. They found that self-reported history of root 
canal therapy had 90% sensitivity, 94% specificity, a positive predictive value of 86% 
and a negative predictive value of 95%  among 58 adult patients to the Harvard School of 
Dental Medicine student dental clinic.105 A more recent study conducted by Gomes et al 
compared self-reported history of ET with ET status determined simultaneously from 
panoramic radiographs. They found that self-reported history of ET had 92% sensitivity, 
89% specificity, 82% positive predictive value, and 95% negative predictive value.106 
Both studies concluded that self-reported history of ET is a highly accurate method to 
predict historic ET.105, 106                 
Individuals who have not received or do not have access to dental care may not 
have received ET when it would be otherwise warranted. We attempted to isolate those 
with access to dental care by stratifying by the median number of teeth and including 
predictors of dental care in our adjusted models but measurement error could persist. 
Residual confounding from unmeasured confounders also cannot be ruled out.   
Conclusion 
ET was not associated with CHD, ischemic stroke, HF, or VTE in our study. 
Further research is needed to elucidate the EI/AP-CVD relationship.  
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Chapter 6 – Manuscript #3: Infection as a Trigger of Cardiovascular Disease: The 
Atherosclerosis Risk in Communities Cohort  
 
Abstract 
Background 
 There is evidence that infection triggers CVD events but the magnitude and duration 
of increased CVD risk following infection is not well understood. Additionally, little is 
known regarding outpatient infection as a CVD trigger. We hypothesized that both all 
infections and outpatient infections are independently associated with risk of CHD, 
ischemic stroke, and VTE and that the infection-CVD association will be stronger among 
total infections compared to outpatient infections and graded such that the association 
will be strongest immediately following the infection and decrease as the time since the 
infection increases. 
Methods 
 CHD, ischemic stroke, and VTE cases were identified in the Atherosclerosis Risk in 
Communities (ARIC) cohort. Hospital discharge diagnosis codes were used to identify 
inpatient infections. Additionally, Medicare claims data linked to ARIC participants were 
used to identify both inpatient and outpatient infections. A case-crossover design and 
conditional logistic regression were used to compare infections among CHD, ischemic 
stroke, and VTE cases (14, 30, 42, and 90 days before the event) with corresponding 
control periods 1 year and 2 years prior.  
Results 
 Infection was associated with higher odds of CHD (14-day OR, 3.8, 30-day OR, 2.9, 
42-day OR, 2.6, and 90-day OR, 2.1), ischemic stroke (14-day OR, 2.6, 30-day OR, 1.9, 
42-day OR, 1.8, and 90-day OR, 1.7), and VTE (14-day OR, 18.9, 30-day OR, 8.0, 42-
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day OR, 5.7, and 90-day OR, 3.6) up to 90 days following infection. The association was 
strongest immediately following the infection and decreased as the time since the 
infection increased. Generally, outpatient infection was a weaker CVD trigger compared 
to all infections.  
Conclusion 
 Patients with an infection should be considered potential candidates for CVD 
prophylaxis. Treatment with standard CVD preventive strategies, including antiplatelet 
agents and statins, should be considered during and immediately after infection to reduce 
the otherwise elevated CVD risk.  
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Introduction 
 Population-based cohort studies have identified many chronic risk factors for 
cardiovascular disease (CVD) that are both modifiable, such as high blood pressure, 
elevated serum cholesterol, and smoking, and non-modifiable, such as male sex, non-
white race, family history, and greater age.5, 6 Acute risk factors – or triggers – of CVD 
are less studied. Identifying and understanding CVD triggers offer potential strategies for 
CVD prevention during vulnerable periods. 
 Prior research has provided evidence that infection triggers acute CVD events 
including MI114, 115, 197, stroke114, 118, 119, and VTE.124 While the results of these studies are 
informative, most previous studies only included hospitalized infections as their exposure 
of interest. Since outpatient encounters for infection are more than 5 times as common as 
inpatient encounters for infection in the United States, assessing the impact of outpatient 
infections on CVD will add to the body of knowledge.11 Further, the magnitude and 
duration of increased cardiovascular risk has varied greatly between studies and remains 
under debate.    
 We expanded upon our prior work linking inpatient infection with stroke118 and 
VTE121 by using the longitudinal data from the Atherosclerosis Risk in Communities 
(ARIC) study and the corresponding ARIC participant data from the Centers for 
Medicare and Medicaid Services (CMS) to examine the relationship between infection 
(both inpatient and outpatient) and outpatient infection only and CVD.  We hypothesized 
that both total infections and outpatient infections will be independently associated with 
risk of CHD, ischemic stroke, and VTE. We further hypothesized that the infection-CVD 
association will be stronger among total infections compared to outpatient infections 
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since inpatient infections are likely more severe and graded such that the infection-CVD 
association will be strongest immediately following the infection and decrease as the time 
since the infection increases.  
Methods 
Study Design 
The ARIC study is a multi-center population-based prospective cohort study 
designed to investigate the etiology and natural history of atherosclerosis in middle-aged 
Americans.158 At baseline in 1987-1989 (visit 1), 15,792 white and black men and 
women were selected from 4 US communities: Forsyth County, North Carolina; Jackson, 
Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland.158 
Subsequent exams took place during 1990 to 1992 (visit 2), 1993 to 1995 (visit 3), 1996 
to 1998 (visit 4), 2011 to 2013 (visit 5), and 2016-2017 (visit 6 currently underway). We 
used a case-crossover study design in which ARIC participants with CVD outcomes 
served as their own controls. The occurrence of infection immediately prior to CVD 
events was compared with preceding time intervals 1 year and 2 years prior to the CVD 
event. The crossover study design is summarized in Figure 9 below. 
Figure 9. Case-crossover study design used to study infection as a CVD trigger, 
ARIC.    
 
 
CHD/Stroke/VTE 
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All ARIC participants with each outcome of interest during follow-up were 
included. CVD events were identified using information collected at each exam, annual 
telephone questionnaires, and hospitalizations. Hospitalizations were identified by 
surveillance of local hospital discharge lists for cohort members. Information obtained at 
study visits, during telephone questionnaires, and through review and abstraction of 
hospital and death records were used to adjudicate CVD outcomes and identify inpatient 
infections.159  Additionally, CMS claims data were used to identify both inpatient and 
outpatient infections in ARIC study participants. CMS claims data for inpatient and 
outpatient services were available since 1991. We excluded individuals who were 
younger than 67 years of age at the time of their CVD event since they were not 
Medicare eligible for both the case and control periods. We also excluded participants 
whose CVD events occurred prior to 1993 to ensure that CMS data were available for 
both case and control periods.  
Inpatient and Outpatient Infection Ascertainment 
 The exposure of interest was infection determined using ICD-9 codes. Inpatient 
hospitalization codes and outpatient visit codes were used to identify infections. Table 27 
below contains the infection types and corresponding ICD-9 codes that were included in 
our exposure of interest. 
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Table 27. Infection type and corresponding ICD-9 codes included in the exposure of 
interest     
Infection ICD-9 Codes 
Other Infectious Diseases 001-139 
Thymus Gland Infection 254.1 
Nervous System Infections 320-326, 331.81 
Eye Infections  372–372.39, 373.0-373.2 
Ear Infections  382-382.4, 383, 386.33, 386.35, 388.60 
Circulatory Infections 390-393, 421-421.1, 422.0, 422.91-422.93 
Respiratory Infections 460–466,472–474.0,475–476.1,478.21–478.24,478.29, 
480-490, 491.1, 494, 510-511, 513.0, 518.6, 519.01  
Digestive Infections 522.5, 522.7, 527.3, 528.3, 540–542, 566–567.9, 569.5, 
572–572.1, 573.1–573.3, 575–575.12 
Urinary Tract Infections 590–590.9, 595–595.4, 597–597.89, 598.0, 599.0 
Male Genital Infections 601–601.9, 604–604.9, 607.1, 607.2, 608.0, 608.4 
Breast Infections 611.0 
Female Pelvic Infections 614–616.1, 616.3–616.4, 616.8 
Puerperal Infections 670 
Skin and Subcutaneous Infections 680–686.9, 706.0 
Musculoskeletal Infections 711–711.9, 730–730.3, 730.8–730.9, 
Blood Infections 790.7–790.8 
Healthcare Acquired Infections 996.60–996.69, 997.62, 998.5, 999.3 
Cardiovascular Events 
 The outcomes of interest were CHD, ischemic stroke, and VTE. The methods used 
for outcome ascertainment included: (1) participants were contacted annually by phone 
and interviewed about interim hospitalizations; (2) local hospitals provided lists of 
hospital discharges with cardiovascular diagnoses that were reviewed to identify cohort 
hospitalizations; and (3) health department death certificate files were regularly surveyed. 
All discharge codes for cohort hospitalizations and listed causes of death from death 
certificates were recorded. CVD events were classified by a combination of computer 
algorithm and adjudicated physician review; disagreements were adjudicated by the 
ARIC Mortality and Morbidity Classification Committee using standardized ARIC 
criteria.159 
 CHD was defined as confirmed CHD death and fatal and nonfatal MI.187 Ischemic 
stroke was identified and classified as thrombotic or cardioembolic stroke based on 
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discharge codes, signs, symptoms, neuroimaging (computerized tomography/magnetic 
resonance imaging), and other diagnostic reports.188 Hemorrhagic strokes were not 
included since no clear biological pathways mediating hemorrhagic stroke risk and 
infection have been proposed or identified.   
 VTE was defined as all PEs and DVTs and restricting DVTs to those that occurred 
in the leg and were identified using diagnosis codes, hospital records, physician and 
consultant reports, and discharge summaries validated according to LITE study 
protocol.168 
Statistical Analysis 
 Each outcome of interest was analyzed separately. The prevalence of infection 14, 
30, 42, and 90 days before CVD events was compared with the corresponding time 
periods exactly 1 year and 2 years before the event. Conditional logistic regression was 
used to estimate odds ratios (OR) of CVD events and 95% confidence intervals (CIs) for 
each time period (14, 30, 42, and 90 days). Separate models were run using all infections 
(both inpatient and outpatient) and outpatient infections only to see if the magnitude of 
the association differed between infection types.  
 Potential confounders that are stable within an individual are controlled in the case-
crossover study design by having cases serve as their own controls. Confounding by 
overall health status related to age is possible because deteriorating health could be a 
common cause of both infection and CVD. As participants age and their health status 
decreases, their CVD risk and risk of infection may increase, suggesting potential 
positive confounding by health status. 
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 To reduce potential confounding, only time periods proximal to the CVD event (1 
year and 2 years before) were included. We further controlled for the total number of 
hospitalizations in the 9 months preceding the start of each of the 3 exposure periods 
(case period and 2 control periods) to account for potential decline in overall health 
status. Since hospitalization is a known VTE trigger, we further controlled for the total 
number of hospitalizations in the 90-day exposure period in the VTE analysis to account 
for non-infection triggering due to hospitalization and isolate the impact of infection. 
Results 
Among the 15,792 ARIC study participants, 2,356 (14.9%) experienced CHD 
(CHD death, fatal and nonfatal MI). Those who were younger than 67 years of age at the 
time of their event (1,017) and those events that occurred prior to 1993 (27) were 
excluded to ensure that CMS data were available for both case and control periods. Our 
final sample size was n=1,312 CHD cases.  
A combined 1,150 (7.3%) ARIC participants experienced an ischemic stroke. We 
excluded those who were younger than 67 years of age at the time of their event (410) 
and those events that occurred prior to 1993 (13) to ensure that CMS data were available 
for both case and control periods. Our final sample size was n=727 ischemic stroke cases.  
Only 845 (5.4%) ARIC participants experienced a VTE event and 755 (4.8%) 
experienced a PE or DVT in the leg. To ensure that CMS data were available for both 
case and control periods, we excluded those who were younger than 67 years of age at 
the time of their event (all - 270 and PE and leg DVT - 239) and those events that 
occurred prior to 1993 (all – 7 and PE and leg DVT - 6). Our final sample size was all 
VTE - n=568 cases, PE and leg DVT – n=510 cases.  
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At-event characteristics of ARIC participants who developed CHD, ischemic 
stroke, and VTE are provided in Table 28 below. The mean age at CVD event was 75 
years. CHD was more common among men (57.4%) while ischemic stroke (54.1%) and 
VTE (56.0%) were more common among women. The majority of events occurred in 
white participants consistent with baseline enrollment.  
Table 28. At-event characteristics of ARIC participants who developed CVD or 
VTE, 1987-2013  
Characteristic CHD  
(n=1,312) 
Ischemic 
Stroke (n=727) 
All VTE 
(n=568) 
PE and Leg 
VTE (n=510) 
Age, years, mean ± SD 75.0 (5.3) 75.1 (5.1) 74.7 (5.2) 74.7 (5.2) 
Sex, count (%)     
   Male 753 (57.4) 334 (45.9) 250 (44.0) 219 (42.9) 
   Female 559 (42.6) 393 (54.1) 318 (56.0) 291 (57.1) 
Race, count (%)     
   White 949 (72.3) 492 (67.7) 341 (60.0) 315 (61.8) 
   Black 359 (27.4) 234 (32.2) 227 (40.0) 195 (38.2) 
   Other 4 (0.3) 1 (0.1) 0 (0.0) 0 (0.0) 
 
 Of the 1,312 CHD cases, 402 (30.6%) had any infection and 366 (27.9%) had an 
outpatient infection in the 90 days preceding their CHD event. Table 29 below contains 
the conditional logistic regression model results for CHD. All infection and outpatient 
infection were more common in all case periods compared with equivalent control 
periods, but the ORs decreased with elapsed time: 14-day OR, 3.8 (95% CI, 2.9–5.0); 30-
day OR, 2.9 (95% CI, 2.3–3.6); 42-day OR, 2.6 (95% CI, 2.1–3.2), and 90-day OR, 2.1 
(95% CI, 1.8–2.6). Controlling for the number of hospitalizations in the 9 month period 
preceding each exposure period slightly attenuated the association between infection and 
CHD. When the exposure of interest was restricted to outpatient infections only, the 
association between infection and CHD was slightly attenuated but remained significant 
at all time points: 14-day OR, 3.3 (95% CI, 2.5, 4.3); 30-day OR, 2.7 (95% CI, 2.1–3.4); 
42-day OR, 2.5 (95% CI, 2.0–3.1), and 90-day OR, 2.0 (95% CI, 1.6–2.4). For both all 
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infections and outpatient infections, the association was strongest in exposure periods 
closest to the CHD event and decreased as the time window before CHD increased.     
Table 29. Association between infection and CHD in the ARIC Cohort, OR, (95% 
CI)  
All Infections Case (n) Control (n) Crude Model Model 1 
14 Days 
   
 
   No Infection 1,135 2,514 Ref Ref 
   Infection 177 110 3.91 (3.00, 5.10) 3.84 (2.94, 5.03) 
30 Days   
 
 
   No Infection 1,059 2,394 Ref Ref 
   Infection 253 230 2.96 (2.38, 3.68) 2.90 (2.33, 3.61) 
42 Days   
 
 
   No Infection 1,022 2,317 Ref Ref 
   Infection 290 307 2.67 (2.17, 3.28) 2.63 (2.14, 3.24) 
90 Days   
 
 
   No Infection 910 2,083 Ref Ref 
   Infection 402 541 2.19 (1.81, 2.64) 2.14 (1.77, 2.58) 
Outpatient Infections     
14 Days     
   No Infection 1,159 2,517 Ref Ref 
   Infection 153 107 3.35 (2.55, 4.50) 3.29 (2.50, 4.32) 
30 Days     
   No Infection 1,084 2,404 Ref Ref 
   Infection 228 220 2.72 (2.17, 3.41) 2.69 (2.14, 3.37) 
42 Days     
   No Infection 1,052 2,333 Ref Ref 
   Infection 260 291 2.47 (1.99, 3.06) 2.45 (1.97, 3.05) 
90 Days     
   No Infection 946 2,109 Ref Ref 
   Infection 366 515 2.02 (1.67, 2.46) 1.99 (1.64, 2.42) 
Model 1: Adjusted for total hospitalizations in the 9 months preceding each exposure 
period  
 
Of the 727 ischemic stroke cases, 186 (25.6%) had any infection and 173 (23.8%) 
had an outpatient infection in the 90 days preceding the stroke event. Table 30 below 
contains the conditional logistic regression model results for infection and ischemic 
stroke. Infection was more common in all case periods compared with equivalent control 
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periods, but the ORs decreased with elapsed time: 14-day OR, 2.6 (1.8, 3.8); 30-day OR, 
1.9 (1.4, 2.5); 42-day OR, 1.8 (1.3, 2.4), and 90-day OR, 1.7 (1.5, 2.2). Controlling for 
the number of hospitalizations in the 9 month period preceding each exposure period 
slightly attenuated the association between infection and ischemic stroke. The association 
between outpatient infection and ischemic stroke was slightly attenuated compared to all 
infections but remained significant at all time points: 14-day OR, 2.4 (1.7, 3.5); 30-day 
OR, 1.7 (1.2, 2.3); 42-day OR, 1.7 (1.3, 2.3), and 90-day OR, 1.7 (1.3, 2.2). Overall, the 
association was strongest in exposure periods closest to the stroke event and decreased as 
the time window before ischemic stroke increased.     
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Table 30. Association between infection and ischemic stroke in the ARIC Cohort, 
OR (95% CI) 
All Infections Case (n) Control (n) Crude Model Model 1 
14 Days 
   
 
   No Infection 652 1,391 Ref Ref 
   Infection 75 63 2.71 (1.88, 3.91) 2.63 (1.82, 3.80) 
30 Days   
 
 
   No Infection 624 1,329 Ref Ref 
   Infection 103 125 1.93 (1.42, 2.62) 1.85 (1.36, 2.52) 
42 Days   
 
 
   No Infection 604 1,295 Ref Ref 
   Infection 123 159 1.85 (1.39, 2.46) 1.78 (1.34, 2.38) 
90 Days   
 
 
   No Infection 541 1,188 Ref Ref 
   Infection 186 266 1.79 (1.39, 2.30) 1.74 (1.5, 2.24) 
Outpatient Infections     
14 Days     
   No Infection 659 1,393 Ref Ref 
   Infection 68 61 2.48 (1.71, 3.60) 2.42 (1.66, 3.53) 
30 Days     
   No Infection 634 1,334 Ref Ref 
   Infection 93 120 1.77 (1.29, 2.41) 1.69 (1.23, 2.31) 
42 Days     
   No Infection 614 1,302 Ref Ref 
   Infection 113 152 1.75 (1.31, 2.35) 1.68 (1.25, 2.26) 
90 Days     
   No Infection 554 1,203 Ref Ref 
   Infection 173 251 1.74 (1.34, 2.26) 1.69 (1.30, 2.20) 
Model 1: Adjusted for total hospitalizations in the 9 months preceding each exposure 
period  
 
 
We observed 568 VTE cases with 270 (47.5%) total infections and 253 (44.5%) 
outpatient infections in the in the 90 days preceding the VTE event and 510 PE and leg 
DVT cases with 237 (46.5%) total infections and 223 (43.7%) outpatient infections in the 
90 days preceding the PE or leg DVT event. Table 31 below contains the conditional 
logistic regression model results for infection and VTE. Infection was more common in 
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all case periods compared with equivalent control periods, but the ORs decrease with 
elapsed time: 14-day OR, 18.9 (10.4, 34.3); 30-day OR, 8.0 (5.4, 11.9); 42-day OR, 5.7 
(4.0, 8.2), and 90-day OR, 3.6 (2.6, 5.0). Controlling for the number of hospitalizations in 
the 9 month period preceding each exposure period did not affect the association between 
infection and VTE. Controlling for the number of hospitalizations in the 90 day exposure 
period slightly attenuated the association. The association between outpatient infection 
and VTE was similar to the association between all infections at all time points: 14-day 
OR, 22.9 (12.2, 43.1); 30-day OR, 8.5 (5.7, 12.9); 42-day OR, 6.3 (4.3, 9.1), and 90-day 
OR, 3.8 (2.7, 5.2). Overall, the association was strongest in exposure periods closest to 
the VTE event and decreased as the time window before VTE increased. Similar results 
were found when the analysis was restricted to PEs and leg DVTs.     
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Table 31. Association between infection and venous thromboembolism in the ARIC Cohort OR, 95% CI 
All Infections Case (n) Control (n) Crude Model Model 1 Model 2 
All VTEs      
14 Days 
   
  
No Infection 388 1,092 Ref Ref Ref 
Infection 180 44 21.35 (12.59, 35.23) 21.32 (12.46, 36.46) 18.85 (10.36, 34.3) 
30 Days   
 
  
No Infection 347 1,044 Ref Ref Ref 
Infection 221 92 11.09 (7.67, 16.05) 11.11 (7.64, 16.17) 7.97 (5.35, 11.88) 
42 Days   
 
  
No Infection 338 1,012 Ref Ref Ref 
Infection 230 124 8.54 (6.16, 11.93) 8.43 (6.01, 11.83) 5.70 (3.98, 8.16) 
90 Days   
 
  
No Infection 298 910 Ref Ref Ref 
Infection 270 226 5.82 (4.35, 7.80) 5.63 (4.19, 7.56) 3.62 (2.63, 4.97) 
PEs & Leg DVTs      
14 Days      
No Infection 351 982 Ref Ref Ref 
Infection 159 38 21.79 (12.35, 38.42) 21.66 (12.20, 38.46) 19.01 (9.96, 36.30) 
30 Days      
No Infection 317 940 Ref Ref Ref 
Infection 193 80 10.68 (7.24, 15.75) 10.66 (7.19, 15.79) 7.57 (4.97, 11.52) 
42 Days      
No Infection 309 910 Ref Ref Ref 
Infection 201 110 8.03 (5.67, 11.39) 7.94 (5.58, 11.30) 5.32 (3.65, 7.74) 
90 Days      
No Infection 273 819 Ref Ref Ref 
Infection 237 201 5.42 (4.00, 7.33) 5.27 (3.88, 7.14) 3.34 (2.40, 4.65) 
Outpatient Infections Case (n) Control (n) Crude Model Model 1 Model 2 
All VTEs      
14 Days      
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No Infection 394 1,097 Ref Ref Ref 
Infection 174 39 21.04 (12.40, 35.72) 21.25 (12.39, 36.45) 22.90 (12.16, 43.14) 
30 Days      
No Infection 356 1,048 Ref Ref Ref 
Infection 212 88 10.72 (7.40, 15.53) 10.73 (7.37, 15.63) 8.53 (5.67, 12.85) 
42 Days      
No Infection 349 1,018 Ref Ref Ref 
Infection 219 118 8.74 (6.19, 12.36) 8.68 (6.11, 12.33) 6.28 (4.32, 9.14) 
90 Days      
No Infection 315 921 Ref Ref Ref 
Infection 253 215 5.69 (4.21, 7.68) 5.54 (4.09, 7.50) 3.77 (2.72, 5.22) 
PEs & Leg DVTs      
14 Days      
No Infection 356 985 Ref Ref Ref 
Infection 154 35 19.94 (11.52, 34.52) 19.98 (11.44, 34.89) 21.16 (10.94, 40.90) 
30 Days      
No Infection 325 941 Ref Ref Ref 
Infection 185 79 9.65 (6.61, 14.11) 9.63 (6.56, 14.14) 7.37 (4.84, 11.21) 
42 Days      
No Infection 318 914 Ref Ref Ref 
Infection 192 106 7.88 (5.53, 11.23) 7.80 (5.45, 11.15) 5.56 (3.79, 8.17) 
90 Days      
No Infection 287 827 Ref Ref Ref 
Infection 223 193 5.15 (3.79, 7.00) 5.01 (3.68, 6.82) 3.37 (2.41, 4.71) 
Model 1: Adjusted for total hospitalizations in the 9 months preceding each exposure period  
Model 2: Adjusted for total hospitalizations in the 9 months and 90 days preceding each exposure period  
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Discussion 
 This case-crossover study within a population-based cohort demonstrated that CHD, 
ischemic stroke, and VTE risk is higher after infection. Patients with infection had higher 
odds of CHD, stroke, and VTE up to 90 days after the infection compared with 
equivalent control periods 1 year and 2 years before the event. This provides evidence in 
support of our hypothesis that infection is associated with higher acute CVD/VTE risk 
and that infection is a CVD/VTE trigger. Generally, the association between infection 
and CVD was weaker when only considering outpatient infections as we hypothesized 
since inpatient infections are likely more severe and trigger a stronger inflammatory 
response. The association between infection and CVD/VTE was also graded such that the 
infection-CVD/VTE association was highest in the exposure periods most proximal to the 
event and decreased as the time window before the event increased.  
Our findings corroborate previous work that has identified a triggering association 
between infection and CVD and that the risk varies by time since infection. Considering 
infection as a trigger of CHD, our results are similar in magnitude to those found by 
Warren-Gash et al (IRR = 4.19)115, Corrales-Medina et al (HR = 4.07)18, and Dalager-
Pedersen et al using hospital controls (RR = 2.32) but smaller  than their analysis using 
population controls (30-day RR = 17.70)114 and the cross-over results of Chew et al (OR 
= 7.5).117   
Our reported associations between infection and ischemic stroke are smaller in 
magnitude compared to the study published by our group that considered the association 
between inpatient infections and ischemic stroke using ARIC data.118 Our results are also 
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smaller effect sizes than those shown by Elkind et al (OR = 7.3)  119 and Fullerton et al 
(OR = 6.3).120 Our results for infection as a trigger of VTE were generally stronger than 
previous studies including a study by our group (OR = 2.65)121,  Chen et al (OR = 1.9)122, 
Dalager-Pedersen et al (DVT HR = 1.78, PE HR = 1.97)123, and  Rogers et al. 
(OR=2.90).124 The unusually strong ORs in our VTE analysis are a function of the high 
percentage of VTE cases that had an infection prior to their event. Since VTE is often 
provoked by cancer, trauma, or immobility, these provoking factors could lead to 
diagnostic bias by which those with a provoking factor are more likely to detect and be 
diagnosed with an infection due to heightened surveillance and more frequent contact 
with healthcare providers. More research is needed to understand the magnitude of VTE 
risk following infection.   
 The primary mechanism linking infection and CVD is through systemic 
inflammation which acutely leads to platelet aggregation and hypercoagulability and 
chronically leads to atherosclerotic development.82  Epaulard et al. summarized existing 
studies that showed that the inflammatory response to infection and the coagulation and 
fibrinolysis processes likely share common pathways, explaining why infection is 
associated with thrombosis and CVD.198 Further, infection can disrupt endothelial 
function that can contribute to the development of and growth of atherosclerosis over 
time.119 Infection may also lead to immobility which can contribute to thrombosis 
through stasis. 
 Our study has a number of strengths, including a large sample size from a 
community cohort, ascertainment of both inpatient and outpatient infection exposure 
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data, a rigorous methodology to adjudicate CVD events, and a crossover design to control 
for potential confounding. It also has limitations. Like all case crossover studies, our 
study may suffer from survival bias as we did not consider infections in participants who 
did not have a CVD event. Our study only considered the relationship between infection 
and CVD among those who survived any infections and later had a CVD event. 
Confounding by age is possible because as participants age their risk of both CVD and 
infection increase. However, to reduce potential confounding by age, only control periods 
1 and 2 years prior to CVD events were examined. We also adjusted for possible 
confounding by the total number of hospitalizations in the 9 month period preceding each 
exposure period. Other confounders that may vary between the exposure and control 
periods were not included. Because we used the hospital admission date as the CVD 
event date, dates for patients who do not seek immediate medical attention may be 
inaccurate, but we think that this is rare because most patients immediately seek care. We 
may be under-ascertaining infections, especially minor ones that did not require care 
since exposure data were collected using hospital and medical claims data. This would 
most likely lead to non-differential misclassification of the exposure that would typically 
bias ORs toward the null.  
Conclusion 
CVD patients had higher odds of infection within 90 days prior to their CVD 
event compared to equivalent control periods 1 and 2 years previous. Both all infections 
and outpatient infections are triggers of CHD, ischemic stroke, and VTE but the 
triggering association may be weaker for outpatient infections.  
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Previous research on CVD triggers has referred to the time period immediately 
following an infection as a “treatable moment” that may hold an opportunity for CVD 
prevention.119 Since inpatient infections appear to be stronger CVD triggers compared to 
outpatient infections, patients with an inpatient infection may be of particular interest for 
CVD prophylaxis. Previous work has also identified infection as a particularly strong 
CVD trigger among those with otherwise low CVD risk.118, 119, 199 CVD prophylaxis 
following an infection may also be particularly relevant for these patients.  There may be 
a role for infection in CVD prevention decision making, though clinical trials and a cost-
benefit analysis should be considered.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 101 
 
Chapter 7 – Conclusion 
There is a growing evidence of an association between infection and 
cardiovascular disease. The overall purpose of this dissertation was to improve the body 
of knowledge related to the relationship between infection and CVD. Specifically, to 
better understand the association between periodontal disease and incident VTE and 
endodontic infection and incident CHD, stroke, heart failure, and VTE; and to better 
understand the triggering effect of infection on CHD, stroke, and VTE.  
 In the first manuscript, we evaluated the impact of periodontal disease on VTE. We 
hypothesized that periodontal disease is independently associated with risk of incident 
VTE and that the risk is graded such that the association between periodontal disease and 
VTE is highest among those with more severe periodontal disease. We found an 
association between self-reported tooth loss due to gum disease and VTE that remained 
significant or borderline significant after adjustment for confounding while the crude 
associations between the clinical periodontal disease classifications were attenuated with 
adjustment and were no longer significant.   
 In the second manuscript, we explored a potential association between endodontic 
therapy and CHD, ischemic stroke, heart failure, and VTE. Our hypothesis was that ET is 
independently associated with risk of incident CHD, incident stroke, incident VTE, and 
incident heart failure and that the association between ET and CVD is graded such that 
those with multiple root canals will be at highest risk of incident CVD events. We found 
no evidence of an association between history of ET and any of our CVD outcomes of 
interest (CHD, ischemic stroke, HF, VTE) that remained after adjustment for 
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confounding in either the overall analysis or among those with more than 24 teeth in the 
stratified analysis.  
 The third manuscript evaluated the role of infection as a trigger of CHD, ischemic 
stroke, and VTE. We hypothesized that both total infections and outpatient infections are 
independently associated with risk of CHD, stroke, and VTE and that the infection-CVD 
association is stronger among total infections compared to outpatient infections only 
since inpatient infection are likely more severe and graded such that the association 
between infection and CVD will be strongest in the exposure periods most proximal to 
the CVD event and decrease as the time window before the event increases. Results from 
the third manuscript provide evidence that infection is a CVD trigger. We demonstrated 
that CHD, ischemic stroke, and VTE risk is higher up to 90 days after an infection and 
that the association between infection and CVD is graded such that CVD risk was highest 
in the exposure periods most proximal to the CVD event and decreased as the time 
window before the event increases. Generally, the association between infection and 
CVD was weaker when only considering outpatient infections as we hypothesized since 
inpatient infections are likely more severe.    
 The results from the three manuscripts collective have a number of implications. 
While prevention and treatment of periodontal infection has a variety of health benefits 
both from a public health and clinical perspective, our results are mixed as to whether 
these measures may reduce VTE risk. While studies investigating the treatment of 
periodontitis as a primary prevention strategy of CVD are lacking, a number of studies 
have investigated the impact of periodontal treatment on CVD risk factors.180 A recent 
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meta-analysis of clinical trials investigating the impact of periodontal treatment of CVD 
risk factors found that periodontal treatment was effective at reducing levels of systemic 
inflammation markers and improving lipid profiles in subjects with periodontititis.151 It is 
unclear from these findings and our mixed results if periodontal treatment could reduce 
VTE risk and further research is needed.  
The prevention, diagnosis, and treatment of endodontic infection have a variety of 
important public health and clinical benefits. The results of our second manuscript do not 
support an association between ET and CVD. The relationship between endodontic 
infection and CVD is still under debate and it is unclear if prevention or treatment of 
endodontic infection as a CVD prevention strategy has merit. A recent systematic review 
found 19 studies that evaluated the association between apical periodontitis and CVD.186 
While 13 of the 19 studies found a positive association between apical periodontitis and 
CVD, 5 found no association and 1 study found a negative association.186 The authors 
conclude that there is considerable heterogeneity among the previous studies in terms of 
their study design, study population, outcomes of interest and AP evaluation methods that 
has produced a lack of quality evidence of a causal relationship.186 While our research 
has expanded the CVD outcomes considered, further research us needed to elucidate the 
endodontic infection-CVD relationship.        
The results of the third manuscript provide evidence in support of our hypothesis 
that infection is a CVD trigger. Patients with an infection should be considered potential 
candidates for CVD prophylaxis. Identification of infection as a CVD trigger may prompt 
more aggressive treatment with standard CVD preventive strategies, including 
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antiplatelet agents and statins, during and immediately after infection to reduce the 
otherwise elevated  CVD risk. Previous research on CVD triggers has referred to the time 
period immediately following an infection as a treatable moment that may hold an 
opportunity for CVD prevention.119 Previous work has identified infection as a 
particularly strong CVD trigger among those with otherwise low CVD risk.118, 119, 199 
CVD prophylaxis following an infection may be particularly relevant for these patients. 
Our results may indicate that patients with an inpatient infection may be of particular 
interest for CVD prophylaxis.   
Although antibiotics have not been shown to prevent vascular events,200-202 
evidence-based infection control efforts such as influenza vaccination may be considered 
because of the ability to not only reduce infection but may also reduce CVD and VTE.203, 
204  
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